<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>g19516exv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;2.1</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>CONFORMED COPY</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">AGREEMENT
    AND PLAN OF MERGER<BR>
    between<BR>
    WEBMD HEALTH CORP.<BR>
    and<BR>
    HLTH CORPORATION<BR>
    Dated as of June&#160;17, 2009</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="18%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="77%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE I DEFINITIONS
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;1.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Certain Defined Terms
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;1.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Interpretation and Rules of Construction
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE II THE MERGER
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    The Merger
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Effective Time; Closing
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Effect of the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Certificate of Incorporation and Bylaws
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;2.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Directors and Officers
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE III EFFECT ON CAPITAL STOCK; EXCHANGE OF CERTIFICATES
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Effect on Capital Stock; Merger Consideration
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Exchange of Certificates
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Stock Transfer Books
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    HLTH Stock Options
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;3.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Restricted Stock
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE IV REPRESENTATIONS AND WARRANTIES OF HLTH
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Corporate Organization
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Capitalization
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Authority Relative to This Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    No Conflict; Required Filings and Consents
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    SEC Filings; Financial Statements
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.06
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Compliance with Laws
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.07
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Absence of HLTH Material Adverse Effect
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.08
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Absence of Litigation
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.09
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Employee Benefit Plans
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Taxes
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Board Approval; Vote Required
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Opinion of Financial Advisor
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.13
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Joint Proxy Statement/Prospectus
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.14
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Brokers
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.15
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Labor
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.16
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Environmental Laws
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;4.17
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Intellectual Property
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE V REPRESENTATIONS AND WARRANTIES OF WEBMD
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Corporate Organization
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Capitalization
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Authority Relative to This Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    No Conflict; Required Filings and Consents
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    SEC Filings; Financial Statement
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.06
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Absence of WebMD Material Adverse Effect
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.07
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Absence of Litigation
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="18%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="77%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.08
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Board Approval; Vote Required
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.09
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ownership of HLTH Capital Stock
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Opinion of Financial Advisor
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Joint Proxy Statement/Prospectus
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;5.12
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Brokers
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE VI CONDUCT OF BUSINESS PENDING THE MERGER
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;6.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Conduct of Business by HLTH Pending the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;6.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Conduct of Business by WebMD Pending the Merger
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE VII ADDITIONAL AGREEMENTS
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Registration Statement and Other SEC Filings
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Stockholders&#146; Meetings
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Access to Information
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Directors&#146; and Officers&#146; Insurance
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Further Action; Reasonable Best Efforts
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.06
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Plan of Reorganization
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.07
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Nasdaq Quotation
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.08
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Public Announcements
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.09
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Assumption of Existing Indentures
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;7.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Notification of Certain Matters
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE VIII CONDITIONS TO THE MERGER
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;8.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Conditions to the Obligations of Each Party
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;8.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Conditions to the Obligations of WebMD
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;8.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Conditions to the Obligations of HLTH
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE IX TERMINATION, AMENDMENT AND WAIVER
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Termination
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Effect of Termination
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Fees and Expenses
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Amendment
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;9.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Waiver
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    ARTICLE X GENERAL PROVISIONS
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.01
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Non-Survival of Representations, Warranties, Covenants and
    Agreements
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.02
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Notices
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.03
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Severability
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.04
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Entire Agreement; Assignment
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.05
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Parties in Interest
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.06
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Specific Performance
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.07
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Governing Law; Jurisdiction
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.08
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Waiver of Jury Trial
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.09
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Headings
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.10
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Counterparts
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;10.11
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Joint Participation in Drafting This Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    ii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="76%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    EXHIBITS
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    Exhibit&#160;2.04
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    WebMD Charter Amendment
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    Exhibit&#160;2.05
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    HLTH Director Classes
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    HLTH DISCLOSURE SCHEDULE
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.01(b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    HLTH Subsidiaries
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.02(a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Capital Stock
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.02(b)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Encumbrances Against HLTH Capital Stock
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.04
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    No Conflicts
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.06
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Compliance with Laws
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.07
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Absence of Certain Changes
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.08
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Litigation
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.09(a)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    HLTH Plans
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.09(g)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Certain Employment Agreements
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.09(h)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    HLTH Equity Awards Outstanding
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.10
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Taxes
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.01
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    HLTH Permitted Deviations from Ordinary Course
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    WEBMD DISCLOSURE SCHEDULE
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.01(b)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    WebMD Subsidiaries
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.02
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    WebMD Permitted Deviations from Ordinary Course
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    iii
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AGREEMENT AND PLAN OF MERGER, dated as of June&#160;17, 2009
    (this &#147;<U>Agreement</U>&#148;), between WEBMD HEALTH CORP.,
    a Delaware corporation (&#147;<U>WebMD</U>&#148;), and HLTH
    CORPORATION, a Delaware corporation (&#147;<U>HLTH</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, upon the terms and subject to the conditions of this
    Agreement and in accordance with the General Corporation Law of
    the State of Delaware (the &#147;<U>DGCL</U>&#148;), WebMD and
    HLTH will enter into a business combination transaction pursuant
    to which HLTH will merge with and into WebMD (the
    &#147;<U>Merger</U>&#148;) with WebMD continuing as the
    surviving company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors of HLTH (the &#147;<U>HLTH
    Board</U>&#148;) has unanimously (i)&#160;approved and declared
    advisable this Agreement, the Merger and the other transactions
    contemplated by this Agreement, (ii)&#160;declared that it is in
    the best interests of the holders of HLTH Common Stock that HLTH
    enter into this Agreement and consummate the Merger and the
    other transactions contemplated by this Agreement on the terms
    and subject to the conditions set forth herein,
    (iii)&#160;directed that the adoption of this Agreement be
    submitted to a vote at a meeting of the holders of HLTH Common
    Stock and (iv)&#160;recommended that the holders of HLTH Common
    Stock adopt this Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors of WebMD (the &#147;<U>WebMD
    Board</U>&#148;), upon the unanimous recommendation of a special
    transaction committee of the WebMD Board consisting solely of
    disinterested directors of WebMD (the &#147;<U>Special
    Committee</U>&#148;), has unanimously (i)&#160;approved and
    declared advisable this Agreement, the Merger and the other
    transactions contemplated by this Agreement, including the
    issuance of shares of Common Stock, par value $0.01 per share,
    of WebMD (&#147;<U>WebMD Common Stock</U>&#148;), in connection
    with the Merger, pursuant to the terms of this Agreement (the
    &#147;<U>Share Issuance</U>&#148;), (ii)&#160;declared that it
    is in the best interests of the holders of Outstanding WebMD
    Capital Stock other than HLTH and the officers and directors of
    HLTH, WebMD and their respective affiliates that WebMD enter
    into this Agreement and consummate the Merger and the other
    transactions contemplated by this Agreement, including the Share
    Issuance, (iii)&#160;directed that the adoption of this
    Agreement and the approval of the transactions contemplated
    hereby be submitted to a vote at a meeting of the holders of
    Outstanding WebMD Capital Stock and (iv)&#160;recommended that
    the holders of Outstanding WebMD Capital Stock adopt this
    Agreement and approve the transactions contemplated
    hereby;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, for federal income Tax purposes, the Merger is intended
    to qualify as a reorganization under the provisions of
    Section&#160;368(a) of the United States Internal Revenue Code
    of 1986, as amended (the &#147;<U>Code</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    NOW, THEREFORE, in consideration of the foregoing and the mutual
    covenants and agreements contained herein, and intending to be
    legally bound hereby, WebMD and HLTH hereby agree as follows:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;I<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">DEFINITIONS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.01&#160;&#160;<I><U>Certain
    Defined Terms</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;For purposes of this Agreement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Action</U>&#148; </I>means any claim, action, suit,
    arbitration, inquiry, proceeding or investigation by or before
    any Governmental Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Affiliate</U>&#148; </I>means, with respect to any
    specific Person, any other Person that directly, or indirectly
    through one or more intermediaries, Controls, is Controlled by,
    or is under common Control with, such specified Person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Beneficial Owner</U>&#148; </I>means, with respect
    to any shares of HLTH Common Stock, the meaning ascribed to such
    term under
    <FONT style="white-space: nowrap">Rule&#160;13d-3(a)</FONT>
    of the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Business Day</U>&#148; </I>means any day that is not
    a Saturday, a Sunday or other day on which the principal offices
    of the SEC in Washington,&#160;D.C. are not open to accept
    filings, or, in the case of determining a
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    date when any payment is due, any day on which banks are
    required or authorized by Law to be closed in the City of New
    York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Competing Transaction</U>,&#148; </I>with respect to
    a party hereto, means any of the following (other than the
    Transactions, the Porex Divestiture and the Little Blue Book
    Divestiture): (i)&#160;any merger, consolidation, share
    exchange, business combination, recapitalization, liquidation,
    dissolution or other similar transaction involving such party
    pursuant to which the stockholders of such party immediately
    preceding such transaction hold securities representing less
    than 90% of the voting power of the surviving entity;
    (ii)&#160;any sale, lease, exchange, transfer or other
    disposition of assets (other than, (A)&#160;in the case of HLTH,
    the sale, lease, exchange, transfer or other disposition of
    Porex and (B)&#160;in the case of WebMD, the sale, lease,
    exchange, transfer or other disposition of Little Blue Book) of
    such party representing more than 10% of the aggregate fair
    market value of the consolidated assets of such party and its
    Subsidiaries; (iii)&#160;any sale, exchange, transfer or other
    disposition of more than 10% of any class of equity securities
    of such party; (iv)&#160;any tender offer or exchange offer
    that, if consummated, would result in any Person beneficially
    owning more than 10% of any class of equity securities of such
    party; (v)&#160;in the case of HLTH, any solicitation in
    opposition to the adoption by HLTH&#146;s stockholders of this
    Agreement; (vi)&#160;in the case of WebMD, any solicitation in
    opposition to the adoption by WebMD&#146;s stockholders of this
    Agreement or the approval by WebMD&#146;s stockholders of the
    Share Issuance; or (vii)&#160;any other transaction the
    consummation of which would reasonably be expected to impede,
    interfere with, prevent or materially delay any of the
    Transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Consent</U>&#148; </I>means any approval, consent,
    license, permit, franchise, grant, order, waiver, authorization,
    confirmation, concession, certificate, exemption, order,
    registration, declaration, filing, report or notice of, with,
    by, or to any Person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Contract</U>&#148; </I>means any agreement,
    instrument, contract, note, bond, mortgage, indenture, lease,
    sublease, license, sublicense, obligation, commitment,
    undertaking or other instrument (other than Governmental
    Approvals).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Control</U>&#148; </I>(including the terms
    &#147;Controlled by&#148; and &#147;under common Control
    with&#148;) with respect to the relationship between or among
    two or more Persons, means the possession, directly or
    indirectly, or as trustee or executor, of the power to direct or
    cause the direction of the affairs or management and policies of
    a Person, whether through the ownership of voting securities, as
    trustee or executor, by contract or credit arrangement or
    otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Convertible Notes</U>&#148; </I>means the
    3<FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">8</FONT>%&#160;Convertible
    Notes due September&#160;1, 2025 issued under the Indenture,
    dated as of August&#160;30, 2005, by and between HLTH
    Corporation (formerly WebMD Corporation) and The Bank of New
    York, as trustee (as amended, modified, supplemented or restated
    from time to time), and the
    1<FONT style="vertical-align: text-top; font-size: 70%;">3</FONT>/<FONT style="font-size: 70%;">4</FONT>%&#160;Convertible
    Subordinated Notes due June&#160;15, 2023 issued under the
    Indenture, dated as of June&#160;25, 2003, by and between HLTH
    Corporation (formerly WebMD Corporation) and The Bank of New
    York, as trustee (as amended, modified, supplemented or restated
    from time to time).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Default</U>&#148; </I>means the occurrence or
    existence of any circumstance which with the passage of time,
    the giving of notice, or both, would constitute or give rise to:
    (i)&#160;a breach, default or violation, (ii)&#160;the creation
    of any Encumbrance (other than a Permitted Encumbrance) or
    (iii)&#160;a right of termination, amendment, renegotiation or
    acceleration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Designated Employee</U>&#148; </I>means any of the
    officers, consultants or employees of HLTH or a HLTH Subsidiary
    whose current annual salaries are in excess of $150,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Encumbrance</U>&#148; </I>means any mortgage,
    pledge, lien, attachment, charge, hypothecation, right of
    set-off or counterclaim, security interest, or other
    encumbrance, security agreement or trust securing any obligation
    of any person or arrangement of any kind.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>End Date</U>&#148; </I>means December&#160;31, 2009.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Environmental Laws</U>&#148; </I>means all Laws
    relating to pollution or protection of the Environment or public
    employee health and safety, including those relating to land
    use, land reclamation, the presence, Release or threatened
    Release of Hazardous Materials, or otherwise relating to the
    manufacture, processing, distribution, use, treatment, storage,
    disposal, transport or handling of Hazardous Materials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Exchange Act</U>&#148; </I>means the Securities
    Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Exchange Fund</U>&#148; </I>means the certificates
    representing whole shares of WebMD Common Stock issued in
    exchange for the Certificates, together with any dividends or
    distributions with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Exchange Ratio</U>&#148; </I>means 0.4444.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Existing Indentures</U>&#148; </I>means (i)&#160;the
    Indenture, dated as of June&#160;25, 2003, by and between HLTH
    Corporation (formerly WebMD Corporation) and The Bank of New
    York, as trustee (as amended, modified, supplemented or restated
    from time to time), and (ii)&#160;the Indenture, dated as of
    August&#160;30, 2005, by and between HLTH Corporation (formerly
    WebMD Corporation d/b/a Emdeon Corporation) and The Bank of New
    York, as trustee (as amended, modified, supplemented or restated
    from time to time).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Governmental Approval</U>&#148; </I>means any
    approval, consent, license, permit, franchise, grant, order,
    waiver, authorization, confirmation, concession, agreement,
    certificate, exemption, order, or registration of, with or by
    any Governmental Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Governmental Authority</U>&#148; </I>means any
    foreign or domestic, federal, national, state, provincial,
    county or local government, governmental, regulatory or
    administrative authority, agency or commission,
    quasi-governmental or supranational authority, or any court,
    tribunal, or judicial or arbitral body.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Governmental Order</U>&#148; </I>means any order,
    writ, judgment, injunction, decree, stipulation, determination
    or award entered by or with any Governmental Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Hazardous Materials</U>&#148; </I>means (i)&#160;any
    &#147;hazardous waste&#148; as defined in the Resource
    Conservation and Recovery Act of 1976 (42&#160;U.S.C.
    Sections&#160;6901 et seq.), as amended through the Closing
    Date, and regulations promulgated thereunder; (ii)&#160;any
    &#147;hazardous substance&#148; as defined in the Comprehensive
    Environmental Response, Compensation and Liability Act of 1980
    (42&#160;U.S.C. Sections&#160;9601 et seq.), as amended through
    the Closing Date, and regulations promulgated thereunder;
    (iii)&#160;petroleum or petroleum products, natural gas, methane
    gas, asbestos or asbestos containing materials, mold, radon, and
    polychlorinated biphenyls; and (iv)&#160;any other chemical,
    material, substance, waste, compound, pollutant, or contaminant
    in any form which is regulated or can give rise to liability
    under any Environmental Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH Common Stock</U>&#148; </I>means shares of
    common stock, par value $0.0001 per share, of HLTH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH Equity Plans</U>&#148; </I>means all stock
    option, restricted stock and other equity-based compensation
    plans and agreements of HLTH (including any plans and agreements
    assumed by HLTH or which cover awards of or relating to HLTH
    Common Stock).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH ERISA Affiliate</U>&#148; </I>means any trade
    or business, whether or not incorporated, which together with
    HLTH would be deemed a &#147;single employer&#148; within the
    meaning of Section&#160;414(b), (c)&#160;or (m)&#160;of the Code
    or Section&#160;4001(b)(1) of ERISA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH Material Adverse Effect</U>&#148; </I>means any
    event, circumstance, change or effect that is or would
    reasonably be expected to have a material adverse effect on the
    results of operations, assets, liabilities or financial
    condition of HLTH and the HLTH Subsidiaries taken as a whole
    (disregarding, for purposes of such determination, HLTH&#146;s
    ownership of WebMD); <U>provided</U>, <U>however</U>, that a
    &#147;HLTH Material Adverse Effect&#148; shall not include any
    event, circumstance, change or effect resulting from
    (a)&#160;changes in general economic conditions or changes in
    the financial or securities markets in general which do not
    affect HLTH disproportionately (relative to other industry
    participants), (b)&#160;the public announcement or the pendency
    of the Transactions, (c)&#160;any action taken by HLTH with the
    consent of WebMD pursuant to Section&#160;6.01 or the failure to
    take any action as to which the consent of WebMD has been
    requested pursuant to Section&#160;6.01 but as to which WebMD
    has withheld its consent, or (d)&#160;any agreement for, the
    public announcement or pendency of, or the consummation of, the
    Porex Divestiture. For the avoidance
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of doubt, no event, circumstance, change or effect relating to
    WebMD <FONT style="white-space: nowrap">and/or</FONT>
    the WebMD Subsidiaries shall be deemed to be, or contribute to,
    any HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH Options</U>&#148; </I>means all options to
    acquire HLTH Common Stock outstanding, whether or not
    exercisable and whether or not vested, at the Effective Time
    under the HLTH Equity Plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>HLTH Subsidiary</U>&#148; </I>means, at the time of
    determination, each Subsidiary of HLTH, other than WebMD and its
    Subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Indebtedness</U>&#148; </I>with respect to a Person
    means, without duplication, (a)&#160;all obligations for
    borrowed money, (b)&#160;all obligations evidenced by bonds,
    debentures, notes or similar instruments, (c)&#160;all
    obligations under conditional sale, repurchase or other title
    retention agreements, (d)&#160;all obligations in respect of the
    deferred purchase price of property or services (other than
    trade payables in the Ordinary Course), (e)&#160;all
    obligations, contingent or otherwise, to purchase, redeem,
    retire or otherwise acquire for value any equity or other
    securities, (f)&#160;all indebtedness of others guaranteed by
    such Person or secured by any Encumbrance, (g)&#160;all
    undischarged monetary obligations in respect of any Governmental
    Order, (h)&#160;all capital lease obligations, synthetic lease
    obligations or obligations arising out of financial hedging
    arrangements, (i)&#160;all obligations, contingent or otherwise,
    as an account party in respect of letters of credit, letters of
    guaranty, bankers&#146; acceptances and similar instruments;
    liability for indebtedness of others arising from such
    Person&#146;s ownership interest in or other relationship with a
    third party, except to the extent the terms of such indebtedness
    provide that such Person is not liable therefor, and
    (j)&#160;all obligations that would be required to be
    capitalized in accordance with GAAP.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Intellectual Property</U>&#148; </I>means all of the
    following as they exist in the United States: (i)&#160;all
    patents, patent applications and statutory invention
    registrations; (ii)&#160;all registered trademarks, service
    marks, trade dress, logos, trade names, and corporate names, and
    (iii)&#160;all registered copyrights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>IRS</U>&#148; </I>means the Internal Revenue Service
    of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Knowledge of HLTH</U>&#148; </I>means the actual
    knowledge after reasonable inquiry of HLTH&#146;s
    &#147;executive officers&#148; as such term is defined under
    Section&#160;16 of the Exchange Act (other than Wayne
    Gattinella).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Knowledge of WebMD</U>&#148; </I>means the actual
    knowledge after reasonable inquiry of WebMD&#146;s
    &#147;executive officers&#148; as such term is defined under
    Section&#160;16 of the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Law</U>&#148; </I>means any federal, national,
    state, provincial, local or similar statute, law, ordinance,
    regulation, rule, code, Governmental Order, requirement or rule
    of law (including common law).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Little Blue Book</U>&#148; </I>means the Little Blue
    Book print directory business of WebMD.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Little Blue Book Divestiture</U>&#148; </I>means any
    full or partial sales or other dispositions, taken as a whole,
    of Little Blue Book by WebMD, whether though a sale of some or
    all of the entities included in Little Blue Book or some or all
    of the assets of Little Blue Book or some other form or forms of
    divestiture transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Nasdaq</U>&#148; </I>means the electronic dealer
    quotation system owned and operated by Nasdaq Stock Market, Inc.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Ordinary Course</U>&#148; </I>means, with respect to
    a Person, the ordinary course of business of such Person,
    consistent with the past practices thereof, including with
    respect to scope, nature, quantity and frequency, and without
    regard for the contemplated Transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Outstanding WebMD Capital Stock</U>&#148; </I>means,
    collectively, the WebMD Class&#160;A Common Stock and the WebMD
    Class&#160;B Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Permitted Encumbrances</U>&#148; </I>means
    (i)&#160;Encumbrances for Taxes that are not yet due and
    payable, and Encumbrances for current Taxes and other charges
    and assessments of any Governmental Authority that may
    thereafter be paid without penalty or that are being contested
    in good faith by appropriate proceedings and for which adequate
    reserves have been established on HLTH&#146;s consolidated books
    and records, (ii)&#160;Encumbrances of carriers, warehousemen,
    mechanics and materialmen and other like
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Encumbrances arising in the Ordinary Course,
    (iii)&#160;Encumbrances of record identified in any title
    reports delivered or made available to WebMD by HLTH,
    (iv)&#160;all Contracts affecting any real property (or any
    portion thereof) identified in the HLTH SEC Reports and
    (v)&#160;any other Encumbrance which could not reasonably be
    expected, individually or in the aggregate, to prevent or
    materially delay the consummation of the Transactions or
    otherwise prevent or materially delay HLTH from performing its
    obligations under this Agreement and could not reasonably be
    expected, individually or in the aggregate, to have a HLTH
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Person</U>&#148; </I>means an individual,
    partnership, firm, corporation, limited liability company,
    association, trust, unincorporated organization, Governmental
    Authority or other entity, as well as any syndicate or group
    that would be deemed to be a Person under Section&#160;13(d)(3)
    of the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Porex</U>&#148; </I>means the business that was
    formerly the Porex segment of HLTH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Porex Divestiture</U>&#148; </I>means any full or
    partial sales or other dispositions, taken as a whole, of Porex,
    including any Porex Surgical Divestiture by HLTH, whether
    through a sale of some or all of the entities included in Porex
    or some or all of the assets of Porex or some other form of
    forms of divestiture transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Porex Surgical Divestiture</U>&#148; </I>means any
    full or partial sale or other dispositions, taken as a whole, of
    the Porex Surgical Products business of Porex, whether through a
    sale of some or all of the entities included in the Porex
    Surgical Products business or some or all of the assets of that
    business or some other form or forms of divestiture transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Release</U>&#148; </I>means any release, spill,
    emission, emptying, leaking, injection, deposit, disposal,
    discharge, dispersal, leaching, pumping, pouring, or migration
    into or through the Environment or into, through or from any
    building or structure.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Representative</U>&#148; </I>means, with respect to
    any Person, any officer, director, employee or advisor or other
    representative of such Person (including any financial advisors,
    legal advisors and accountants).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Securities Act</U>&#148; </I>means the Securities
    Act of 1933, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Subsidiary</U>&#148; </I>means any entity with
    respect to which a specified Person (i)&#160;has, directly or
    indirectly, the power, through the ownership of securities or
    otherwise, to elect a majority of directors or similar managing
    body or (ii)&#160;owns, directly or indirectly, a majority of
    the equity interests.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Superior Proposal</U>&#148; </I>means any bona fide
    proposal with respect to a Competing Transaction received by a
    party hereto after the date hereof which the HLTH Board of
    Directors or the Special Committee, as applicable, determines in
    good faith, after consultation with its legal counsel, is
    reasonably capable of being consummated, and would, if
    consummated in accordance with its terms, be more favorable to
    the stockholders (in their capacity as such) of such party than
    the Merger; <U>provided</U>, that, for purposes of this
    definition of &#147;Superior Proposal,&#148; each reference to
    &#147;10%&#148; and &#147;90%&#148; in the definition of
    &#147;Competing Transaction&#148; shall be deemed to be a
    reference to &#147;50%&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Tax</U>&#148; </I>means any and all taxes of any
    kind whatsoever (together with any and all interest, penalties,
    additions to tax and additional amounts imposed with respect
    thereto) imposed by any Governmental Authority, including
    income, franchise, windfall or other profits, gross receipts,
    property, sales, use, capital stock, payroll, employment, social
    security, estimated withholding, ad valorem, stamp, transfer,
    value added and similar taxes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>Triggering Event</U>&#148; </I>with respect to a
    party hereto shall be deemed to have occurred if: (i)&#160;the
    Board of Directors of such party shall have recommended to the
    stockholders of such party a Competing Transaction or shall have
    resolved to do so or shall have entered into any letter of
    intent or similar document or any agreement, contract or
    commitment accepting any Competing Transaction; or (ii)&#160;a
    tender offer or exchange offer for 15% or more of the
    outstanding shares of capital stock of such party is commenced,
    and the Board of Directors of such party fails to recommend
    against acceptance of such tender offer or exchange offer by its
    stockholders (including by taking no position with respect to
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    acceptance of such tender offer or exchange offer by its
    stockholders) or (iii)&#160;the Board of Directors of such party
    withdraws, modifies or changes its recommendation of this
    Agreement or the Merger in a manner adverse to the other party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>WebMD Class&#160;B Common Stock</U>&#148; </I>means
    the Class&#160;B Common Stock, par value $0.01 per share, of
    WebMD.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>WebMD Equity Plans</U>&#148; </I>means the WebMD
    Health Corp. 2005 Long-Term Incentive Plan and the WebMD Health
    Corp. Long-Term Incentive Plan for Employees of Subimo LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;<U>WebMD Material Adverse Effect</U>&#148; </I>means
    any event, circumstance, change or effect that is or would
    reasonably be expected to have a material adverse effect on the
    results of operations, assets, liabilities or financial
    condition of WebMD and the WebMD Subsidiaries taken as a whole;
    <U>provided</U>, <U>however</U>, that a &#147;WebMD Material
    Adverse Effect&#148; shall not include any event, circumstance,
    change or effect resulting from (a)&#160;changes in general
    economic conditions or changes in the financial or securities
    markets in general which do not affect WebMD disproportionately
    (relative to other industry participants), (b)&#160;general
    changes in the industries in which WebMD and its Subsidiaries
    operate which do not affect WebMD disproportionately (relative
    to other industry participants), (c)&#160;the public
    announcement or pendency of the Transactions, (d)&#160;any
    action taken by WebMD with the consent of HLTH pursuant to
    Section&#160;6.02 or the failure to take any action as to which
    the consent of HLTH has been requested pursuant to
    Section&#160;6.02 but as to which HLTH has withheld its consent
    or (e)&#160;any agreement for, the public announcement or
    pendency of, or the consummation of, the Little Blue Book
    Divestiture.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The following terms have the meaning assigned thereto
    in the Sections set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="18%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Defined Term</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Location of Definition</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Action
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Affiliate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beneficial Owner
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue Sky Laws
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.04(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business Day
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certificate of Merger
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.02
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certificates
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;3.02(b)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Closing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.02
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Closing Date
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.02
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Code
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Competing Transaction
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Consent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible Notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Default
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Designated Employee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    DGCL
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective Time
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.02
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Encumbrance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    End Date
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Environmental Laws
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ERISA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.09(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="18%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Defined Term</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Location of Definition</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Agent
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;3.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Fund
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange Ratio
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Existing Indentures
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;9.03
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Filed HLTH SEC Documents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Article&#160;IV
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Filed WebMD SEC Documents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Article V
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    GAAP
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.05(b)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Governmental Approval
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Governmental Authority
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Governmental Order
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hazardous Materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Board
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Disclosure Schedule
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Article&#160;IV
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Equity Plans
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH ERISA Affiliate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Material Adverse Effect
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH New Preferred Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Plans
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.09(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Preferred Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH SEC Reports
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.05(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Stockholders&#146; Meeting
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;7.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    HLTH Subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Indebtedness
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Intellectual Property
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    IRS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Joint Proxy Statement/Prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;7.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Knowledge of HLTH
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Knowledge of WebMD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Law
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Little Blue Book
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Little Blue Book Divestiture
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merger
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merger Consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;3.01(b)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Multiemployer Plan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.09(b)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Nasdaq
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ordinary Course
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding WebMD Capital Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Permitted Encumbrances
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Person
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Porex
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="18%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Defined Term</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Location of Definition</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Porex Divestiture
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Porex Surgical Divestiture
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reference Price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;3.02(d)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Registration Statement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;7.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Release
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Representative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;3.05
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Satisfaction Date
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.02
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;4.05(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Securities Act
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Share Issuance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Special Committee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Superior Proposal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Surviving Corporation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.01
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Terminating HLTH Breach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;9.01(h)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Terminating WebMD Breach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;9.01(i)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transactions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.01
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Triggering Event
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Preamble
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Board
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Charter Amendment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;2.04(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Class&#160;A Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Class&#160;B Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Disclosure Schedule
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Article V
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Material Adverse Effect
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;1.01(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Preferred Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;5.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD SEC Reports
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;5.05(a)
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Stockholders&#146; Meeting
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;7.02(a)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    WebMD Subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    &#167;&#160;5.01(a)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>1.02&#160;&#160;<I><U>Interpretation
    and Rules of Construction</U>.</I>&#160;&#160;In this Agreement,
    except to the extent otherwise provided or the context otherwise
    requires:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;when a reference is made in this Agreement to an
    Article, Section, Exhibit or Schedule, such reference is to an
    Article or Section of, or an Exhibit or Schedule to, this
    Agreement unless otherwise indicated;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;the table of contents and headings for this Agreement
    are for reference purposes only and do not affect in any way the
    meaning or interpretation of this Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;whenever the words &#147;include,&#148;
    &#147;includes&#148; or &#147;including&#148; are used in this
    Agreement, they are deemed to be followed by the words
    &#147;without limitation&#148;;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;the words &#147;hereof,&#148; &#147;herein&#148; and
    &#147;hereunder&#148; and words of similar import, when used in
    this Agreement, refer to this Agreement as a whole and not to
    any particular provision of this Agreement;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;the words &#147;material&#148; and
    &#147;materially&#148; and words of similar import, when used in
    this Agreement with respect to a representation or warranty, are
    to be understood by reference to the businesses, assets,
    properties of HLTH and the HLTH Subsidiaries or WebMD and the
    WebMD Subsidiaries, as the case may be, taken as a whole;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;references to the business, operations, properties,
    assets, liabilities, rights or obligations of HLTH or HLTH and
    the HLTH Subsidiaries shall be understood to exclude the
    business, operations, properties, assets, liabilities, rights or
    obligations of WebMD and the WebMD Subsidiaries and, for
    avoidance of doubt, all references to HLTH shall be understood
    to exclude WebMD and the WebMD Subsidiaries;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;all terms defined in this Agreement have the defined
    meanings when used in any certificate or other document made or
    delivered pursuant hereto, unless otherwise defined therein;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;the definitions contained in this Agreement are
    applicable to the singular as well as the plural forms of such
    terms;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;references to a Person are also to its successors (by
    merger or otherwise) and permitted assigns.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;II<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">THE MERGER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.01&#160;&#160;<I><U>The
    Merger</U>.</I>&#160;&#160;Upon the terms and subject to the
    conditions set forth in Article&#160;VIII, and in accordance
    with the DGCL, at the Effective Time (as defined in
    Section&#160;2.02), HLTH shall be merged with and into WebMD. As
    a result of the Merger, the separate corporate existence of HLTH
    shall cease and WebMD shall continue as the surviving company of
    the Merger (the &#147;<U>Surviving Corporation</U>&#148;). The
    Merger, the Share Issuance and the other transactions
    contemplated by this Agreement (other than the Porex Divestiture
    and the Little Blue Book Divestiture) are referred to in this
    Agreement collectively as the &#147;Transactions.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.02&#160;&#160;<I><U>Effective
    Time; Closing</U>.</I>&#160;&#160;No later than the second
    Business Day following the satisfaction or, if permissible,
    waiver of the conditions set forth in Article&#160;VIII (the
    &#147;<U>Satisfaction Date</U>&#148;), a closing (the
    &#147;<U>Closing</U>&#148;) shall be held at the offices of
    Shearman&#160;&#038; Sterling LLP, 599 Lexington Avenue, New
    York, New&#160;York 10022, or at such other place, time
    <FONT style="white-space: nowrap">and/or</FONT> date
    as the parties shall agree, for the purpose of confirming the
    satisfaction or waiver, as the case may be, of the conditions
    set forth in Article&#160;VIII (the date of the Closing being
    referred to as, the &#147;<U>Closing Date</U>&#148;). On the
    Closing Date, WebMD shall file a certificate of merger (the
    &#147;<U>Certificate of Merger</U>&#148;) with the Secretary of
    State of the State of Delaware, in such form as is required by,
    and executed in accordance with, the relevant provisions of the
    DGCL (the date and time of such filing of the Certificate of
    Merger (or such later time as may be agreed by each of the
    parties hereto and specified in the Certificate of Merger) being
    the &#147;<U>Effective Time</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.03&#160;&#160;<I><U>Effect
    of the Merger</U>.</I>&#160;&#160;At the Effective Time, the
    effect of the Merger shall be as provided in the applicable
    provisions of the DGCL. Without limiting the generality of the
    foregoing, and subject thereto, at the Effective Time, all the
    property, rights, privileges, powers and franchises of HLTH
    shall vest in the Surviving Corporation, and all debts,
    liabilities, obligations, restrictions, disabilities and duties
    of HLTH shall become the debts, liabilities, obligations,
    restrictions, disabilities and duties of the Surviving
    Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.04&#160;&#160;<I><U>Certificate
    of Incorporation and Bylaws</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;At the Effective Time, the Restated Certificate of
    Incorporation of WebMD shall be amended in its entirety in the
    form of Exhibit&#160;2.04 attached hereto (the &#147;<U>WebMD
    Charter Amendment</U>&#148;) and, as so amended, shall be the
    Restated Certificate of Incorporation of the Surviving
    Corporation until duly amended or repealed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;Effective as of the Effective Time, the Amended and
    Restated Bylaws of WebMD, as in effect immediately prior to the
    Effective Time, shall be the Bylaws of the Surviving Corporation
    until thereafter amended as provided therein or by applicable
    Law.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>2.05&#160;&#160;<I><U>Directors
    and Officers</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;Immediately following the Effective Time, the number of
    directors constituting the whole WebMD Board shall be increased
    to a number that allows for adding to the WebMD Board the
    directors of HLTH who are not directors of WebMD. The directors
    of WebMD and HLTH immediately prior to the Effective Time shall
    be the directors of the Surviving Corporation and shall hold
    office until their respective successors are duly elected or
    appointed and qualified or until their earlier death, removal or
    resignation. The directors of HLTH who are not, immediately
    prior to the Effective Time, on the WebMD Board shall be added
    to the class of directors as set forth in Exhibit&#160;2.05.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The officers of WebMD immediately prior to the
    Effective Time shall be the officers of the Surviving
    Corporation and shall hold office until their respective
    successors are duly elected or appointed and qualified or until
    their earlier death, removal or resignation.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;III<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">EFFECT ON
    CAPITAL STOCK; EXCHANGE OF CERTIFICATES
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.01&#160;&#160;<I><U>Effect
    on Capital Stock; Merger Consideration</U>.</I>&#160;&#160;At
    the Effective Time, by virtue of the Merger:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Cancellation of Treasury Stock and WebMD-Owned
    Stock</U>.</I>&#160;&#160;Each share of HLTH Common Stock held
    in the treasury of HLTH, and each share of HLTH Common Stock
    owned by WebMD or any direct or indirect wholly-owned Subsidiary
    of WebMD or of HLTH immediately prior to the Effective Time,
    shall be cancelled without any conversion thereof and no payment
    or distribution shall be made with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Conversion of HLTH Common
    Stock</U>.</I>&#160;&#160;At the Effective Time, each share of
    HLTH Common Stock (other than any shares to be cancelled
    pursuant to Section&#160;3.01(a)) shall be cancelled and shall
    be converted automatically, payable upon surrender, in the
    manner provided in Section&#160;3.02, of the certificate
    formerly evidencing such share, into the right to receive a
    number of shares of WebMD Common Stock equal to the Exchange
    Ratio (the &#147;<U>Merger Consideration</U>&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Effect on WebMD Capital
    Stock</U>.</I>&#160;&#160;Each share of the capital stock of
    WebMD not owned by HLTH or any HLTH Subsidiary issued and
    outstanding immediately prior to the Effective Time shall remain
    issued and outstanding after the Effective Time, and each share
    of capital stock of WebMD owned by HLTH or any HLTH Subsidiary
    shall be canceled without any conversion thereof and no payment
    or distribution shall be made with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.02&#160;&#160;<I><U>Exchange
    of Certificates</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Exchange Agent</U>.</I>&#160;&#160;Prior to the
    Effective Time, and in any case not later than the date on which
    HLTH shall mail the Joint Proxy Statement/Prospectus to the
    holders of HLTH Common Stock, WebMD shall enter into an
    agreement with American Stock Transfer&#160;&#038;
    Trust&#160;Company or such other bank or trust company that may
    be designated by WebMD and is reasonably acceptable to HLTH to
    serve as the exchange agent (the &#147;<U>Exchange
    Agent</U>&#148;) in connection with the conversion of HLTH
    Common Stock contemplated by this Article&#160;III. At or
    immediately subsequent to the Effective Time, WebMD shall
    authorize the Exchange Agent to issue an aggregate number of
    shares of WebMD Common Stock equal to the Merger Consideration,
    as well as the certificates evidencing such shares. WebMD shall
    make available to the Exchange Agent, for addition to the
    Exchange Fund, from time to time as needed, cash sufficient to
    pay cash in lieu of fractional shares in accordance with
    Section&#160;3.02(d).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Exchange Procedures</U>.</I>&#160;&#160;As
    promptly as practicable after the Effective Time, WebMD shall
    cause the Exchange Agent to mail to each person who was, at the
    Effective Time, a holder of record of shares of HLTH Common
    Stock entitled to receive the Merger Consideration pursuant to
    Section&#160;3.01: (i)&#160;a letter of transmittal (which shall
    be in customary form and shall specify that delivery shall be
    effected, and risk of loss and title to the certificates
    evidencing such shares (together with any book entry shares, the
    &#147;<U>Certificates</U>&#148;) shall pass, only
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    upon proper delivery of the Certificates to the Exchange Agent)
    and (ii)&#160;instructions for use in effecting the surrender of
    the Certificates pursuant to such letter of transmittal,
    including instructions for use in effecting surrender of
    Certificates (or attaching affidavits of loss in lieu thereof)
    or non-certificated shares represented by book-entry. In
    addition, HLTH shall use its best efforts to make the letter of
    transmittal available to all Persons who become holders of HLTH
    Common Stock during the period between such record date and the
    date of the HLTH Stockholders&#146; Meeting. Upon surrender to
    the Exchange Agent of a Certificate for cancellation, together
    with such letter of transmittal, duly completed and validly
    executed in accordance with the instructions thereto, and such
    other documents as may be required pursuant to such
    instructions, the holder of such Certificate shall be entitled
    to receive in exchange therefor the Merger Consideration in the
    form of a certificate representing that number of whole shares
    of WebMD Common Stock which such holder has the right to receive
    in respect of the shares of HLTH Common Stock formerly
    represented by such Certificate (after taking into account all
    shares of HLTH Common Stock then held by such holder), and the
    Certificate so surrendered shall forthwith be cancelled. Until
    surrendered as contemplated by this Section&#160;3.02, each
    Certificate shall be deemed at all times after the Effective
    Time to represent only the right to receive upon surrender the
    Merger Consideration in accordance with the terms of this
    Agreement with respect to the shares of HLTH Common Stock
    formerly represented thereby. In the event of a transfer of
    ownership of shares of HLTH Common Stock that is not registered
    in the transfer or stock records of HLTH, any cash to be paid
    upon, or shares of WebMD Common Stock to be issued upon due
    surrender of the Certificate formerly representing such shares
    of HLTH Common Stock may be paid or issued, as the case may be,
    to the transferee if such Certificate is presented to the
    Exchange Agent, accompanied by all documents required to
    evidence and effect such transfer and to evidence that any
    applicable stock transfer or similar Taxes have been paid or are
    not applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Distributions with Respect to Unexchanged Shares
    of WebMD Common Stock</U>.</I>&#160;&#160;No dividends or other
    distributions declared or made after the Effective Time with
    respect to WebMD Common Stock with a record date after the
    Effective Time shall be paid to the holder of any unsurrendered
    Certificate the right of receipt of which is represented
    thereby, until the holder of such Certificate shall surrender
    such Certificate. Subject to the effect of escheat, tax or other
    applicable Laws, following surrender of any such Certificate,
    there shall be paid to the holder of the certificates
    representing whole shares of WebMD Common Stock issued in
    exchange therefor, without interest, (i)&#160;promptly, the
    amount of any cash payable with respect to a fractional share of
    WebMD Common Stock to which such holder is entitled pursuant to
    this Article&#160;III and the amount of dividends or other
    distributions with a record date after the Effective Time and
    theretofore paid with respect to such whole shares of WebMD
    Common Stock, and (ii)&#160;at the appropriate payment date, the
    amount of dividends or other distributions, with a record date
    after the Effective Time but prior to surrender and a payment
    date occurring after surrender, payable with respect to such
    whole shares of WebMD Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;<I><U>No Fractional Shares</U>.</I>&#160;&#160;No
    certificates or scrip representing fractional shares of WebMD
    Common Stock shall be issued upon the surrender for exchange of
    Certificates, and such fractional share interests will not
    entitle the owner thereof the right to vote or to any other
    rights of a shareholder of WebMD. Each holder of a fractional
    share interest shall be paid an amount in cash (without
    interest) equal to the product obtained by multiplying
    (i)&#160;such fractional share interest to which such holder
    (after taking into account all fractional share interests then
    held by such holder) would otherwise be entitled by
    (ii)&#160;the closing price of a share of WebMD Class&#160;A
    Common Stock on the Nasdaq on the last trading day immediately
    preceding the Effective Time (the &#147;<U>Reference
    Price</U>&#148;). As promptly as practicable after the
    determination of the amount of cash, if any, to be paid to
    holders of fractional share interests, the Exchange Agent shall
    so notify WebMD, and WebMD shall deposit such amount with the
    Exchange Agent and shall cause the Exchange Agent to forward
    payments to such holders of fractional share interests subject
    to and in accordance with the terms of this Article&#160;III.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;<I><U>No Further Ownership
    Rights</U>.</I>&#160;&#160;The Merger Consideration issued (and
    paid) in accordance with the terms of this Article&#160;III upon
    conversion of any shares of HLTH Common Stock shall be deemed to
    have been issued (and paid) in full satisfaction of all rights
    pertaining to such shares of HLTH Common Stock subject, however,
    to WebMD&#146;s obligation to pay any dividends or make any
    other distributions with a record date prior to the Effective
    Time that may have been declared or made by HLTH on such shares
    of HLTH Common Stock
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in accordance with the terms of this Agreement or prior to the
    date of this Agreement and which remain unpaid at the Effective
    Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;<I><U>Adjustments to Exchange
    Ratio</U>.</I>&#160;&#160;The Exchange Ratio shall be adjusted
    to reflect appropriately the effect of any stock split, reverse
    stock split, stock dividend (including any dividend or
    distribution of securities convertible into WebMD Class&#160;A
    Common Stock or HLTH Common Stock), extraordinary cash
    dividends, reorganization, recapitalization, reclassification,
    combination, exchange of shares or other like change with
    respect to WebMD Class&#160;A Common Stock or HLTH Common Stock
    occurring on or after the date hereof and prior to the Effective
    Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;<I><U>Termination of Exchange
    Fund</U>.</I>&#160;&#160;Any portion of the Exchange Fund
    (including any interest and other income received with respect
    thereto) that remains undistributed to the holders of the shares
    of HLTH Common Stock for six months after the Effective Time
    shall be delivered to WebMD, upon demand, and any holders of the
    shares of HLTH Common Stock who have not theretofore complied
    with this Article&#160;III shall thereafter look only to WebMD
    for the Merger Consideration and any dividends or other
    distributions with respect to WebMD Common Stock to which they
    are entitled pursuant to this Article&#160;III. Any portion of
    the Exchange Fund (including any interest and other income
    received with respect thereto) remaining unclaimed by holders of
    shares of HLTH Common Stock as of a date which is immediately
    prior to such time as such amounts would otherwise escheat to or
    become property of any Governmental Authority shall, to the
    extent permitted by applicable Law, become the property of WebMD
    free and clear of any claims or interest of any Person
    previously entitled thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;<I><U>No Liability</U>.</I>&#160;&#160;WebMD shall not
    be liable to any holder of shares of HLTH Common Stock for any
    share of WebMD Common Stock (or dividends or distributions with
    respect thereto), or cash properly delivered to a public
    official pursuant to any abandoned property, escheat or similar
    Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;<I><U>Withholding Rights</U>.</I>&#160;&#160;WebMD
    shall be entitled to deduct and withhold from the Merger
    Consideration otherwise payable pursuant to this Agreement to
    any holder of shares of HLTH Common Stock such amounts as it is
    required to deduct and withhold with respect to the making of
    such payment under the Code, or any provision of state, local or
    foreign Tax Law. To the extent that amounts are so withheld by
    WebMD, such withheld amounts shall be treated for all purposes
    of this Agreement as having been paid to the holder of the
    shares of HLTH Common Stock in respect of which such deduction
    and withholding was made by WebMD.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;<I><U>Lost Certificates</U>.</I>&#160;&#160;If any
    Certificate shall have been lost, stolen or destroyed, upon the
    making of an affidavit of that fact by the Person claiming such
    Certificate to be lost, stolen or destroyed and, if required by
    WebMD, the posting by such Person of a bond, in such reasonable
    amount as WebMD may direct, as indemnity against any claim that
    may be made against it with respect to such Certificate, the
    Exchange Agent will issue in exchange for such lost, stolen or
    destroyed Certificate the applicable Merger Consideration, any
    cash in lieu of fractional shares of WebMD Common Stock to which
    the holders thereof are entitled and any dividends, other
    distributions or payments of principal or interest to which the
    holders thereof are entitled pursuant to this Article&#160;III.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.03&#160;&#160;<I><U>Stock
    Transfer Books</U>.</I>&#160;&#160;At the Effective Time, the
    stock transfer books of HLTH shall be closed and there shall be
    no further registration of transfers of shares of HLTH Common
    Stock thereafter on the records of HLTH. From and after the
    Effective Time, the holders of Certificates representing shares
    of HLTH Common Stock outstanding immediately prior to the
    Effective Time shall cease to have any rights with respect to
    such shares of HLTH Common Stock, except as otherwise provided
    in this Agreement or by Law. If, after the Effective Time, any
    Certificates are presented to the Exchange Agent or WebMD for
    any reason for transfer, they shall be cancelled and exchanged
    for the proper Merger Consideration subject to and in accordance
    with the terms and requirements of this Article&#160;III.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.04&#160;&#160;<I><U>HLTH
    Stock Options</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>HLTH Options</U>.</I>&#160;&#160;All HLTH Options
    shall remain outstanding following the Effective Time. At the
    Effective Time, the HLTH Options shall, by virtue of the Merger
    and without any further action on the part of HLTH or the holder
    thereof, be assumed by WebMD in such manner as described herein.
    From and after the Effective Time, all references to HLTH in the
    HLTH Equity Plans and the applicable stock option agreements
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    issued thereunder shall be deemed to refer to WebMD, which shall
    have assumed the HLTH Equity Plans and such stock option
    agreements as of the Effective Time by virtue of this Agreement
    and without any further action. Each HLTH Option assumed by
    WebMD (each, a &#147;<U>Substitute Option</U>&#148;) shall be
    exercisable upon the same terms and conditions as under the
    applicable HLTH Equity Plan and the applicable option agreement
    issued thereunder (including vesting provisions and provisions
    regarding acceleration of vesting upon certain transactions),
    except that (A)&#160;each such Substitute Option shall be
    exercisable for (or shall become exercisable in accordance with
    its terms), and represent the right to acquire, that number of
    shares of WebMD Common Stock equal to the product of
    (i)&#160;the number of shares of HLTH Common Stock subject to
    such HLTH Option immediately prior to the Effective Time
    multiplied by (ii)&#160;the Exchange Ratio, and (B)&#160;the
    option price per share of WebMD Common Stock shall be an amount
    (rounded up to the nearest cent) equal to the quotient of
    (i)&#160;the exercise price per share of HLTH Common Stock
    subject to each HLTH Option immediately prior to the Effective
    Time divided by (ii)&#160;the Exchange Ratio. Notwithstanding
    the foregoing, the exercise price of, and number of shares
    subject to, (i)&#160;each Substitute Option shall be determined
    in order to comply with Section&#160;409A of the Code, and (ii)
    (x)&#160;any fractional share of WebMD Common Stock resulting
    from an aggregation of all the shares of a holder subject to any
    HLTH Option shall be rounded down to the nearest whole share and
    (y)&#160;for any HLTH Option to which Section&#160;421 of the
    Code applies by reason of its qualification under
    Section&#160;422 of the Code, the option price, the number of
    shares purchasable pursuant to such option and the terms and
    conditions of exercise of such option shall be determined in
    order to comply with Section&#160;424 of the Code. Each
    Substitute Option shall otherwise be subject to the same terms
    and conditions as such HLTH Option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Substitute Options</U>.</I>&#160;&#160;As soon as
    practicable after the Effective Time, WebMD shall deliver, or
    cause to be delivered, to each holder of a Substitute Option an
    appropriate notice setting forth such holder&#146;s rights
    pursuant thereto and such Substitute Option shall continue in
    effect on the same terms and conditions (including any
    antidilution provisions, and subject to the adjustments required
    by this Section&#160;3.04 after giving effect to the Merger).
    WebMD shall comply with the terms of all such Substitute Options
    and operate with the intent, subject to the provisions of the
    HLTH Equity Plans, that (i)&#160;Substitute Options that
    qualified as incentive stock options under Section&#160;422 of
    the Code prior to the Effective Time continue to qualify as
    incentive stock options after the Effective Time and
    (ii)&#160;the assumption of each HLTH Option will satisfy the
    requirements of Treasury
    <FONT style="white-space: nowrap">Regulation&#160;Section&#160;1.409A-1(b)(5)(v)(D)</FONT>
    so as not to be treated as the grant of a new stock right or a
    change in the form of payment for purposes of Section&#160;409A
    of the Code. WebMD shall take all corporate action necessary to
    reserve for issuance a sufficient number of shares of WebMD
    Common Stock for delivery upon exercise of Substitute Options
    pursuant to the terms set forth in this Section&#160;3.04. As
    soon as practicable after the Effective Time, the shares of
    WebMD Common Stock subject to Substitute Options will be covered
    by an effective registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    (or any successor form) or another appropriate form, and WebMD
    shall use its reasonable efforts to maintain the effectiveness
    of such registration statement or registration statements for so
    long as Substitute Options remain outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Section&#160;16 of the Exchange
    Act</U>.</I>&#160;&#160;On or after the date of the Agreement
    and prior to the Effective Time, each of WebMD and HLTH shall
    take all necessary action such that, with respect to each member
    of the HLTH Board and each employee of HLTH that is subject to
    Section&#160;16 of the Exchange Act, the acquisition by such
    Person of WebMD Common Stock or Substitute Options in the Merger
    and the disposition by any such Person of WebMD Common Stock,
    HLTH Options or Restricted Shares (as defined in
    Section&#160;3.05) pursuant to the Transactions contemplated by
    this Agreement shall be exempt from the short-swing profit
    liability rules of Section&#160;16(b) of the Exchange Act
    pursuant to
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    promulgated thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>3.05&#160;&#160;<I><U>Restricted
    Stock</U>.</I>&#160;&#160;If any shares of HLTH Common Stock
    (the &#147;<U>Restricted Shares</U>&#148;) outstanding
    immediately prior to the Effective Time are unvested or are
    subject to a repurchase option, risk of forfeiture or other
    condition under any HLTH Equity Plan or other agreement with
    HLTH, then each such holder of Restricted Shares shall, at the
    Effective Time, for each Restricted Share held, receive a number
    of shares of WebMD Common Stock equal to the Exchange Ratio;
    provided, however, that the aggregate number of shares of WebMD
    Common Stock each holder of Restricted Shares receives pursuant
    to this Section&#160;3.05 shall be rounded to the nearest whole
    number in the event such holder would otherwise receive a
    fractional
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    share. The shares of WebMD Common Stock issued in exchange for
    such shares of HLTH Common Stock will also be unvested and
    subject to the same vesting schedule, repurchase option, risk of
    forfeiture or other condition, and the certificates representing
    such shares of WebMD Common Stock may accordingly be marked with
    appropriate legends. HLTH shall take all actions that may be
    necessary to ensure that, from and after the Effective Time,
    WebMD is entitled to exercise any such repurchase options or
    other rights set forth in any such restricted stock purchase or
    other agreement.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IV<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF HLTH
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as set forth in the correspondingly-numbered sections and
    subsections of the HLTH Disclosure Schedule that has been
    delivered by HLTH to WebMD in connection with the execution and
    delivery of this Agreement (the &#147;<U>HLTH Disclosure
    Schedule</U>&#148;) or as disclosed in the reports, schedules,
    forms, statements and other documents filed by HLTH with the SEC
    and publicly available prior to the date of this Agreement (the
    &#147;<U>Filed HLTH SEC Documents</U>&#148;), HLTH hereby
    represents and warrants to WebMD that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.01&#160;&#160;<I><U>Corporate
    Organization</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;Each of HLTH and each HLTH Subsidiary is a corporation
    or a limited liability company duly organized, validly existing
    and in good standing under the laws of the jurisdiction of its
    incorporation or organization and has the requisite corporate or
    limited liability company power and authority and all necessary
    Governmental Approvals to own, lease and operate its properties
    and to carry on its business as it is now being conducted,
    except where the failure to be so organized, existing or in good
    standing or to have such power, authority and Governmental
    Approvals could not reasonably be expected, individually or in
    the aggregate, to prevent or materially delay consummation of
    the Transactions or otherwise prevent or materially delay HLTH
    from performing its obligations under this Agreement and could
    not reasonably be expected, individually or in the aggregate, to
    have a HLTH Material Adverse Effect. Each of HLTH and each HLTH
    Subsidiary is duly qualified or licensed as a foreign
    corporation or limited liability company to do business, and is
    in good standing, in each jurisdiction where the character of
    the properties owned, leased or operated by it or the nature of
    its business makes such qualification or licensing necessary,
    except where the failure to be so qualified or licensed and in
    good standing could not reasonably be expected, individually or
    in the aggregate, to prevent or materially delay consummation of
    the Transactions or otherwise prevent or materially delay HLTH
    from performing its obligations under this Agreement and could
    not reasonably be expected, individually or in the aggregate, to
    have a HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;A true and complete list of each HLTH Subsidiary,
    together with the jurisdiction of incorporation or organization
    and the percentage of the outstanding capital stock or
    membership interest of each such HLTH Subsidiary owned by HLTH
    (directly or indirectly), is set forth in Section&#160;4.01(b)
    of the HLTH Disclosure Schedule. HLTH does not directly or
    indirectly own any equity or similar interest in, or any
    interest convertible into or exchangeable or exercisable for any
    equity or similar interest in, any corporation, partnership,
    joint venture or other business association or entity (other
    than WebMD and the WebMD Subsidiaries).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.02&#160;&#160;<I><U>Capitalization</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The authorized capital stock of HLTH consists of
    (i)&#160;900,000,000&#160;shares of HLTH Common Stock,
    (ii)&#160;4,990,000&#160;shares of preferred stock, par value
    $0.0001 per share, designated &#147;New Preferred Stock&#148;
    (&#147;<U>HLTH New Preferred Stock</U>&#148;) and
    (iii)&#160;10,000&#160;shares of preferred stock, par value
    $0.0001 per share, designated &#147;Preferred Stock&#148;
    (&#147;<U>HLTH Preferred Stock</U>&#148;). As of June&#160;11,
    2009, (i)&#160;102,784,797&#160;shares of HLTH Common Stock are
    issued and outstanding, all of which are validly issued, fully
    paid and nonassessable, (ii)&#160;355,592,322&#160;shares of
    HLTH Common Stock are held in the treasury of HLTH, and
    (iii)&#160;no shares of HLTH Common Stock are held by HLTH
    Subsidiaries. As of May&#160;31, 2009, 2,525,557&#160;shares of
    HLTH Common Stock are reserved for future issuance pursuant to
    outstanding employee stock options or restricted stock granted
    pursuant to the HLTH Equity Plans. As of the date of this
    Agreement, no shares of HLTH New Preferred Stock or HLTH
    Preferred Stock are issued and outstanding. Except for
    outstanding awards issued
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    under the HLTH Equity Plans, there are no options, warrants or
    other rights, agreements, arrangements or commitments of any
    character relating to the issued or unissued capital stock of
    HLTH or obligating HLTH or any HLTH Subsidiary to issue or sell
    any shares of capital stock of, or other equity interests in,
    HLTH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;All of the issued and outstanding shares or other
    ownership interests of each HLTH Subsidiary are duly authorized,
    validly issued, fully paid and nonassessable, and each such
    share or other ownership interest is owned by HLTH or another
    HLTH Subsidiary free and clear of all Encumbrances. There are no
    options, warrants or other rights, agreements, arrangements or
    commitments of any character relating to the issued or unissued
    capital stock of any HLTH Subsidiary or obligating any HLTH
    Subsidiary to issue or sell any shares of capital stock of, or
    other equity interests in, any HLTH Subsidiary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.03&#160;&#160;<I><U>Authority
    Relative to This Agreement</U>.</I>&#160;&#160;HLTH has all
    necessary corporate power and authority to execute and deliver
    this Agreement, to perform its obligations hereunder and to
    consummate the Transactions. The execution and delivery of this
    Agreement by HLTH and the consummation by HLTH of the
    Transactions have been duly and validly authorized by all
    necessary corporate action, and no other corporate proceedings
    on the part of HLTH are necessary to authorize this Agreement or
    to consummate the Transactions (other than the adoption of this
    Agreement by the stockholders of HLTH and the filing of the
    Certificate of Merger as contemplated by Section&#160;2.02. This
    Agreement has been duly and validly executed and delivered by
    HLTH and, assuming the due authorization, execution and delivery
    by WebMD, constitutes a legal, valid and binding obligation of
    HLTH, enforceable against HLTH in accordance with its terms,
    subject to the effect of any applicable bankruptcy, insolvency
    (including all laws relating to fraudulent transfers),
    reorganization, moratorium or similar laws affecting
    creditors&#146; rights generally and subject to the effect of
    general principles of equity (regardless of whether considered
    in a proceeding at law or in equity).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.04&#160;&#160;<I><U>No
    Conflict; Required Filings and Consents</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The execution and delivery of this Agreement by HLTH do
    not, and the performance of this Agreement by HLTH will not
    (i)&#160;constitute a Default under the certificate of
    incorporation or bylaws or any equivalent or other
    organizational documents of HLTH or any HLTH Subsidiary,
    (ii)&#160;assuming that all Governmental Approvals and other
    actions described in Section&#160;4.04(b) have been obtained and
    all filings and notifications described in Section&#160;4.04(b)
    have been made, conflict with or violate any Law applicable to
    HLTH or any HLTH Subsidiary or by which any property or asset of
    HLTH or any HLTH Subsidiary is bound or affected, or
    (iii)&#160;constitute a Default under any Contract to which HLTH
    or any HLTH Subsidiary is a party or by which HLTH or any HLTH
    Subsidiary or any of their assets or properties is bound or
    affected, except, with respect to clauses&#160;(ii) and (iii),
    for any such Defaults which could not reasonably be expected,
    individually or in the aggregate, to prevent or materially delay
    consummation of the Transactions or otherwise prevent or
    materially delay HLTH from performing its obligations under this
    Agreement and could not reasonably be expected, individually or
    in the aggregate, to have a HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The execution and delivery of this Agreement by HLTH do
    not, and the performance of this Agreement by HLTH will not,
    require any Governmental Approval, or filing with or
    notification to, any Governmental Authority except (i)&#160;for
    applicable requirements, if any, of the Exchange Act, state
    securities or &#147;blue sky&#148; laws (&#147;<U>Blue Sky
    Laws</U>&#148;) and state takeover laws, and filing and
    recordation of appropriate merger documents as required by the
    DGCL, and (ii)&#160;where the failure to obtain such
    Governmental Approval, or to make such filings or notifications,
    could not reasonably be expected, individually or in the
    aggregate, to prevent or materially delay consummation of the
    Transactions, or otherwise prevent or materially delay HLTH from
    performing its obligations under this Agreement, and could not
    reasonably be expected, individually or in the aggregate, to
    have a HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.05&#160;&#160;<I><U>SEC
    Filings; Financial Statements</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;HLTH has filed all forms, reports and documents
    required to be filed by it with the Securities and Exchange
    Commission (the &#147;<U>SEC</U>&#148;) since December&#160;31,
    2008 (collectively, &#147;<U>HLTH SEC Reports</U>&#148;). As of
    their respective dates, or, if amended or superseded by a
    subsequent filing made prior to the date hereof, as of the date
    of the last such amendment or superseding filing prior to the
    date hereof, the HLTH SEC Reports filed prior to the date of
    this Agreement complied, and the HLTH SEC Reports filed
    subsequent to the date of this
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Agreement will comply, in all material respects with the
    requirements of the Securities Act and the Exchange Act, as the
    case may be, and the applicable rules and regulations
    promulgated thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;Each of the consolidated financial statements
    (including, in each case, any notes thereto) contained in the
    HLTH SEC Reports and the consolidated balance sheet of HLTH as
    at March&#160;31, 2009 was prepared in accordance with United
    States generally accepted accounting principles
    (&#147;<U>GAAP</U>&#148;) applied on a consistent basis
    throughout the periods indicated (except as may be indicated in
    the notes thereto or, in the case of unaudited statements, as
    permitted by
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    of the SEC) and each fairly presents, in all material respects,
    the consolidated financial position, results of operations and
    cash flows of HLTH and the consolidated HLTH Subsidiaries as of
    the respective dates thereof and for the respective periods
    indicated therein, except as otherwise noted therein (subject,
    in the case of unaudited statements, to normal and recurring
    year-end adjustments which, individually or in the aggregate,
    have not had, and could not reasonably be expected to have, a
    HLTH Material Adverse Effect).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Except as and to the extent reflected and reserved
    against in the consolidated balance sheet of HLTH and the
    consolidated HLTH Subsidiaries as at March&#160;31, 2009
    (including the notes thereto), neither HLTH nor any HLTH
    Subsidiary has any liability, obligation or Indebtedness that
    would be required to be reflected on a balance sheet (or the
    notes thereto) prepared in accordance with GAAP, except for
    (i)&#160;liabilities, obligations and Indebtedness incurred in
    the Ordinary Course since March&#160;31, 2009,
    (ii)&#160;liabilities, obligations and Indebtedness incurred in
    connection with the Porex Divestiture and
    (iii)&#160;liabilities, obligations and Indebtedness which are
    not, individually or in the aggregate, material to HLTH and the
    HLTH Subsidiaries taken as a whole and which could not,
    individually or in the aggregate, reasonably be expected to
    prevent or materially delay consummation of the Transactions or
    otherwise prevent or materially delay HLTH from performing its
    obligations under this Agreement and could not reasonably be
    expected, individually or in the aggregate, to have a HLTH
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.06&#160;&#160;<I><U>Compliance
    with Laws</U>.</I>&#160;&#160;Each of HLTH and each HLTH
    Subsidiary is in compliance with, and is not in Default under,
    any Law, Governmental Order, permit or license applicable to
    HLTH and each HLTH Subsidiary, except for any such failure to
    comply or Default as would not, individually or in the
    aggregate, prevent or materially delay the consummation of the
    Transactions or otherwise prevent or materially delay HLTH from
    performing its obligations under this Agreement or, individually
    or in the aggregate, result in a HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.07&#160;&#160;<I><U>Absence
    of HLTH Material Adverse Effect</U>.</I>&#160;&#160;Since
    March&#160;31, 2009 through the date of this Agreement, except
    as expressly contemplated by this Agreement, there has not been
    any HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.08&#160;&#160;<I><U>Absence
    of Litigation</U>.</I>&#160;&#160;As of the date hereof, there
    is no Action pending or, to the Knowledge of HLTH, threatened
    against HLTH or any HLTH Subsidiary, or any property or asset of
    HLTH or any HLTH Subsidiary, before any Governmental Authority
    that (a)&#160;individually or in the aggregate, has had, or
    could reasonably be expected to have, a HLTH Material Adverse
    Effect, (b)&#160;seeks to materially delay or prevent the
    consummation of the Transactions or (c)&#160;relates to the
    transactions contemplated by, or the validity of, this Agreement
    and which seeks damages or any equitable relief. As of the date
    hereof, neither HLTH nor any HLTH Subsidiary nor any material
    property or asset of HLTH or any HLTH Subsidiary is subject to
    any Governmental Order that could reasonably be expected,
    individually or in the aggregate, to prevent or materially delay
    consummation of the Transactions or otherwise prevent or
    materially delay HLTH from performing its obligations under this
    Agreement or could reasonably be expected, individually or in
    the aggregate, to have a HLTH Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.09&#160;&#160;<I><U>Employee
    Benefit Plans</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;Section&#160;4.09(a) of the HLTH Disclosure Schedule
    lists, as of the date hereof, (i)&#160;all employee benefit
    plans (as defined in Section&#160;3(3) of the Employee
    Retirement Income Security Act of 1974, as amended
    (&#147;<U>ERISA</U>&#148;)), and all bonus, stock option, stock
    purchase, restricted stock, phantom stock or other stock-based
    compensation, incentive, deferred compensation, retiree medical
    or life insurance, supplemental retirement, severance or other
    material benefit plans, agreements, policies or programs, and,
    with respect to the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Designated Employees, all employment, termination, severance,
    change in control, retention or other contracts or agreements to
    which HLTH or any HLTH Subsidiary is a party, with respect to
    which HLTH or any HLTH Subsidiary has or could incur any
    material obligation or which are maintained, contributed to or
    sponsored by HLTH or any HLTH Subsidiary for the benefit of any
    current or former employee, officer or director of HLTH or any
    HLTH Subsidiary, (ii)&#160;each employee benefit plan for which
    HLTH or any HLTH Subsidiary could incur liability under
    Section&#160;4069 of ERISA in the event such plan has been or
    were to be terminated, and (iii)&#160;any plan in respect of
    which HLTH or any HLTH Subsidiary could incur liability under
    Section&#160;4212(c) of ERISA (collectively, &#147;<U>HLTH
    Plans</U>&#148;). All HLTH Plans are in writing and have been
    provided or made available to WebMD.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;None of the HLTH Plans is a multiemployer plan (within
    the meaning of Section&#160;3(37) or 4001(a)(3) of ERISA) (a
    &#147;<U>Multiemployer Plan</U>&#148;) and neither HLTH nor any
    HLTH Subsidiary or HLTH ERISA Affiliate has in the past six
    years sponsored or contributed to, or had any liability or
    obligation in respect of, any Multiemployer Plan or a plan that
    is subject to the minimum funding requirements of
    Section&#160;412 of the Code or Title&#160;IV of ERISA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Each HLTH Plan is now and always has been operated in
    all material respects in accordance with its terms and the
    requirements of all applicable Laws, except where such
    non-compliance could not reasonably be expected, individually or
    in the aggregate, to have a HLTH Material Adverse Effect. HLTH
    and each HLTH Subsidiary has performed all material obligations
    required to be performed by it under, is not in any material
    respect in Default under, and has no knowledge of any material
    Default by any party to, any HLTH Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;Each HLTH Plan that is intended to be qualified under
    Section&#160;401(a) or Section&#160;401(k) of the Code has
    timely received a favorable determination letter which has not
    been revoked, opinion letter or advisory letter from the IRS
    that is so qualified and, to the Knowledge of HLTH, no fact or
    event has occurred since the date of such determination letter
    or letters from the IRS that would reasonably be expected to
    adversely affect the qualified status of any such HLTH Plan or
    the exempt status of any related trust.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;To the Knowledge of HLTH, there has not been any
    prohibited transaction (within the meaning of Section&#160;406
    of ERISA or Section&#160;4975 of the Code) with respect to any
    HLTH Plan. Neither HLTH nor any HLTH Subsidiary has incurred any
    liability under, arising out of or by operation of Title&#160;IV
    of ERISA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;None of the HLTH Plans provides medical, health or life
    insurance or any other welfare-type benefits (other than
    severance benefits payable under an employment agreement) for
    current or future retired or terminated employees of HLTH or the
    HLTH Subsidiaries or their spouses or dependents (other than in
    accordance with Part&#160;6 of Title&#160;I of ERISA or
    Section&#160;4980B of the Code or applicable state laws).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;Neither the execution and delivery of this Agreement
    nor the consummation of the Transactions will constitute a
    Default, result in any payment becoming due, or materially
    increase the amount of compensation or benefits due, to any
    current or former employee of HLTH or the HLTH Subsidiaries or,
    with respect to any HLTH Plan, (i)&#160;increase any benefits
    otherwise payable under any HLTH Plan or result in any
    requirement to fund any HLTH Plan; (ii)&#160;result in the
    acceleration of the time of payment or vesting of any such
    compensation or benefits; (iii)&#160;result in a non-exempt
    prohibited transaction (within the meaning of Section&#160;406
    of ERISA or Section&#160;4975 of the Code); (iv)&#160;limit or
    restrict the right to merge, amend or terminate any HLTH Plan;
    or (v)&#160;result in the payment of any amount that would,
    individually or in combination with any other such payment,
    reasonably be expected to constitute an &#147;excess parachute
    payment&#148; as defined in Section&#160;280G(b)(1) of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;Section&#160;4.09(h) of the HLTH Disclosure Schedule
    lists the number of vested and unvested stock options,
    restricted stock or other equity awards outstanding under each
    applicable HLTH Plan as of May&#160;31, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.10&#160;&#160;<I><U>Taxes</U>.</I>&#160;&#160;Each
    of HLTH and each HLTH Subsidiary has filed all Tax returns and
    reports required to be filed by them and have paid and
    discharged all Taxes owed by HLTH and the HLTH Subsidiaries,
    except where the failure to file such Tax Returns or pay such
    Taxes would not, individually or in the aggregate, reasonably be
    expected to have a HLTH Material Adverse Effect. All such Tax
    returns are true, accurate and complete in all material
    respects. HLTH and each HLTH Subsidiary has withheld and paid
    all
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    material Taxes required to be withheld or paid in connection
    with amounts paid or owing to any employee or otherwise. Neither
    the IRS nor any other United States or
    <FONT style="white-space: nowrap">non-United</FONT>
    States taxing authority or agency is now asserting or, to the
    Knowledge of HLTH, threatening to assert, against HLTH or any
    HLTH Subsidiary any material deficiency or claim for any Taxes
    or interest thereon or penalties in connection therewith. The
    accruals and reserves for Taxes reflected in the consolidated
    balance sheet of HLTH and the consolidated HLTH Subsidiaries as
    of December&#160;31, 2008 are adequate to cover all Taxes
    accruable through such date (including interest and penalties,
    if any, thereon) in accordance with GAAP and there will be no
    increase in accruals or reserves for Taxes from such date
    through the Effective Time other than for the items arising in
    the Ordinary Course or in connection with the Transactions or
    the Porex Divestiture. There are no material Tax Encumbrances
    upon any property or assets of HLTH or any of HLTH Subsidiaries
    except Encumbrances for current property Taxes not yet due or
    that are being contested in good faith. Neither HLTH nor any
    HLTH Subsidiary is required to include in income in any Tax
    period ending after the Closing Date any adjustment pursuant to
    Section&#160;481 of the Code by reason of a voluntary change in
    accounting method initiated by HLTH or any HLTH Subsidiary, and
    the IRS has not initiated or proposed any such adjustment or
    change in accounting method. Neither HLTH nor any HLTH
    Subsidiary has been a &#147;distributing corporation&#148; or a
    &#147;controlled corporation&#148; in a distribution intended to
    qualify under Section&#160;355(e) of the Code within the past
    five years. To the Knowledge of HLTH, neither HLTH nor any of
    its Affiliates has taken or agreed to take any action that would
    prevent the Merger from qualifying as a reorganization within
    the meaning of Section&#160;368(a) of the Code. HLTH is not
    aware of any agreement, plan or other circumstance that would
    prevent the Merger from qualifying as a reorganization within
    the meaning of Section&#160;368(a) of the Code. There are no
    outstanding agreements or waivers extending the statutory period
    of limitation applicable to any material Tax assessment or
    deficiency with respect to HLTH and each of the HLTH
    Subsidiaries. Neither HLTH nor any of the HLTH Subsidiaries is a
    real property holding company within the meaning of
    Section&#160;897 of the Code. Neither HLTH nor any of the HLTH
    Subsidiaries has entered into a closing agreement with, or
    requested a ruling from, the IRS or any other taxing authority
    during the last three years. Neither HLTH nor any of its
    Subsidiaries will be required to include any item of income in,
    or exclude any item of deduction from, taxable income for any
    taxable period or portion thereof ending after the Closing Date
    as a result of any deferred intercompany gain or excess loss
    account described in Treasury regulations under
    Section&#160;1502 of the Code (or any similar provision of
    state, local or foreign law) attributable to the period prior to
    the Closing. Neither HLTH nor any of the HLTH Subsidiaries has
    participated in any &#147;listed transaction&#148; or other
    &#147;reportable transaction&#148; within the meaning of
    Treasury
    <FONT style="white-space: nowrap">Regulation&#160;Section&#160;1.6011-4.</FONT>
    As of December&#160;31, 2008, (i)&#160;the HLTH consolidated
    group, in the aggregate, has estimated net operating loss
    carryforwards in the amount, and subject to the expiration
    periods and limitation under Section&#160;382 of the Code, set
    forth in Section&#160;4.10 of the HLTH Disclosure Schedule and
    (ii)&#160;WebMD and its Subsidiaries, in the aggregate, has
    estimated net operating loss carryforwards in the amount, and
    subject to the expiration periods and limitation under
    Section&#160;382 of the Code, set forth in Section&#160;4.10 of
    the HLTH Disclosure Schedule.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.11&#160;&#160;<I><U>Board
    Approval; Vote Required</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The HLTH Board, at a meeting duly called and held
    pursuant to the DGCL and HLTH&#146;s organizational documents,
    adopted resolutions which were not subsequently rescinded or
    modified in any way (i)&#160;approving and declaring advisable
    this Agreement, the Merger and the other Transactions,
    (ii)&#160;declaring that it is in the best interests of the
    stockholders of HLTH that HLTH enter into this Agreement and
    consummate the Transactions, (iii)&#160;directing that the
    adoption of this Agreement be submitted to a vote at a meeting
    of the stockholders of HLTH and (iv)&#160;recommending that the
    stockholders of HLTH adopt this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The only vote of the holders of any class or series of
    capital stock of HLTH necessary to adopt this Agreement is the
    affirmative vote of the holders of a majority of the outstanding
    shares of HLTH Common Stock in favor thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.12&#160;&#160;<I><U>Opinion
    of Financial Advisor</U>.</I>&#160;&#160;HLTH has received the
    written opinion of Raymond James&#160;&#038; Associates, Inc.,
    dated the date of this Agreement, to the effect that, as of such
    date, the Exchange Ratio is fair, from a financial point of
    view, to the holders of shares of HLTH Common Stock, a copy of
    which opinion has been delivered to WebMD.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.13&#160;&#160;<I><U>Joint
    Proxy Statement/Prospectus</U>.</I>&#160;&#160;The information
    supplied by HLTH for inclusion in the Joint Proxy
    Statement/Prospectus will not, at (i)&#160;the time the
    Registration Statement is declared effective, (ii)&#160;the time
    the Joint Proxy Statement/Prospectus (or any amendment thereof
    or supplement thereto) is first mailed to the stockholders of
    HLTH and WebMD, (iii)&#160;the time of each of the HLTH
    Stockholders&#146; Meeting and the WebMD Stockholders&#146;
    Meeting and (iv)&#160;the Effective Time, contain any untrue
    statement of a material fact or fail to state any material fact
    required to be stated therein or necessary in order to make the
    statements therein, in light of the circumstances under which
    they were made, not misleading.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.14&#160;&#160;<I><U>Brokers</U>.</I>&#160;&#160;No
    broker, finder or investment banker (other than Raymond
    James&#160;&#038; Associates, Inc.) is entitled to any
    brokerage, finder&#146;s or other fee or commission in
    connection with the Transactions based upon arrangements made by
    or on behalf of HLTH. HLTH has heretofore furnished to WebMD a
    complete and correct copy of all agreements between HLTH and
    Raymond James&#160;&#038; Associates, Inc. pursuant to which
    such firm would be entitled to any payment relating to the
    Transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.15&#160;&#160;<I><U>Labor</U>.</I>&#160;&#160;Neither
    HLTH nor any HLTH Subsidiary is party to any collective
    bargaining agreement or other agreement or arrangement with a
    labor union, labor organization, workers council or other
    similar body and no such agreement is currently being
    negotiated. As of the date hereof, to the Knowledge of HLTH,
    there are no ongoing union certification drives or pending
    proceedings for certifying a union with respect to employees of
    HLTH or any HLTH Subsidiary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.16&#160;&#160;<I><U>Environmental
    Laws</U>.</I>&#160;&#160;Except as would not, individually or in
    the aggregate, reasonably be expected to have a HLTH Material
    Adverse Effect, (i)&#160;there are no, and there have not been
    any, Hazardous Materials at any property currently owned or
    leased, or to the Knowledge of HLTH, formerly owned or leased by
    HLTH, or any HLTH Subsidiary under circumstances that have
    resulted in or are reasonably likely to result in liability of
    HLTH or any HLTH Subsidiary under any applicable Environmental
    Laws; and (ii)&#160;neither HLTH nor any HLTH Subsidiary has
    received any written notification (nor to the Knowledge of HLTH
    are there any facts existing that would reasonably be expected
    to give rise to such a notification) alleging that it is liable
    for, or request for information pursuant to Section&#160;104(e)
    of the Comprehensive Environmental Response, Compensation and
    Liability Act or similar Law concerning any Release or
    threatened Release of Hazardous Materials or any other
    Environmental Law at any location except, with respect to any
    such notification or request for information concerning any such
    Release or threatened Release, to the extent such matter has
    been fully resolved with the appropriate Governmental Authority.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>4.17&#160;&#160;<I><U>Intellectual
    Property</U>.</I>&#160;&#160;Each of HLTH and the HLTH
    Subsidiaries owns, or is licensed to use, all Intellectual
    Property material to its business, and the use thereof by HLTH
    and the HLTH Subsidiaries does not infringe upon the
    intellectual property rights of any other person, except to the
    extent that any such failure to own or license, or any such
    infringements individually or in the aggregate, could not
    reasonably be expected to have a HLTH Material Adverse Effect.
    To the Knowledge of HLTH, such Intellectual Property has not
    been infringed or challenged, except to the extent that any such
    infringements or challenges individually or in the aggregate,
    could not reasonably be expected to have a HLTH Material Adverse
    Effect.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;V<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">REPRESENTATIONS
    AND WARRANTIES OF WEBMD
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as set forth in the correspondingly-numbered sections and
    subsections of the WebMD Disclosure Schedule that has been
    delivered by WebMD to HLTH in connection with the execution and
    delivery of this Agreement (the &#147;<U>WebMD Disclosure
    Schedule</U>&#148;) or as disclosed in the reports, schedules,
    forms, statements and other documents filed by WebMD with the
    SEC and publicly available prior to the date of this Agreement
    (the &#147;<U>Filed WebMD SEC Documents</U>&#148;), WebMD hereby
    represents and warrants to HLTH that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.01&#160;&#160;<I><U>Corporate
    Organization</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;Each of WebMD and each Subsidiary of WebMD (each a
    &#147;<U>WebMD Subsidiary</U>&#148;) is a corporation or a
    limited liability company duly organized, validly existing and
    in good standing under the laws of the jurisdiction of its
    incorporation or organization and has the requisite corporate or
    limited liability company
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    power and authority and all necessary Governmental Approvals to
    own, lease and operate its properties and to carry on its
    business as it is now being conducted, except where the failure
    to be so organized, existing or in good standing or to have such
    power, authority and Governmental Approvals could not reasonably
    be expected, individually or in the aggregate, to prevent or
    materially delay consummation of the Transactions or otherwise
    prevent or materially delay WebMD from performing its
    obligations under this Agreement, and could not reasonably be
    expected, individually or in the aggregate, to have a WebMD
    Material Adverse Effect. Each of WebMD and each WebMD Subsidiary
    is duly qualified or licensed as a foreign corporation or
    limited liability company to do business, and is in good
    standing, in each jurisdiction where the character of the
    properties owned, leased or operated by it or the nature of its
    business makes such qualification or licensing necessary, except
    where the failure to be so qualified or licensed and in good
    standing could not reasonably be expected, individually or in
    the aggregate, to prevent or materially delay consummation of
    the Transactions or otherwise prevent or materially delay WebMD
    from performing its obligations under this Agreement and could
    not reasonably be expected, individually or in the aggregate, to
    have a WebMD Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;A true and complete list of all WebMD Subsidiaries,
    together with the jurisdiction of incorporation or organization
    of each WebMD Subsidiary and the percentage of the outstanding
    capital stock or membership interest of each WebMD Subsidiary
    owned by WebMD and each other WebMD Subsidiary, is set forth in
    Section&#160;5.01(b) of the WebMD Disclosure Schedule. WebMD
    does not directly or indirectly own any equity or similar
    interest in, or any interest convertible into or exchangeable or
    exercisable for any equity or similar interest in, any
    corporation, partnership, joint venture or other business
    association or entity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.02&#160;&#160;<I><U>Capitalization</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The authorized capital stock of WebMD consists of
    (i)&#160;500,000,000&#160;shares of WebMD Class&#160;A Common
    Stock, (ii)&#160;150,000,000&#160;shares of WebMD Class&#160;B
    Common Stock and (iii)&#160;50,000,000&#160;shares of preferred
    stock, par value $0.01 per share (&#147;<U>WebMD Preferred
    Stock</U>&#148;). As of June&#160;11, 2009,
    (i)&#160;9,598,401&#160;shares of WebMD Class&#160;A Common
    Stock and (ii)&#160;48,100,000&#160;shares of WebMD Class&#160;B
    Common Stock are issued and outstanding, all of which are
    validly issued, fully paid and nonassessable,
    (iii)&#160;453,155&#160;shares of WebMD Class&#160;A Common
    Stock are held in the treasury of WebMD, and (iv)&#160;no shares
    of WebMD Class&#160;A Common Stock are held by WebMD
    Subsidiaries. As of May&#160;31, 2009, 2,173,720&#160;shares of
    WebMD Class&#160;A Common Stock are reserved for future issuance
    pursuant to outstanding employee stock options or stock
    incentive rights granted pursuant to the WebMD Equity Plans. As
    of the date of this Agreement, no shares of WebMD Preferred
    Stock are issued and outstanding. Except for outstanding awards
    issued under the WebMD Equity Plans, there are no options,
    warrants or other rights, agreements, arrangements or
    commitments of any character relating to the issued or unissued
    capital stock of WebMD or any WebMD Subsidiary or obligating
    WebMD or any WebMD Subsidiary to issue or sell any shares of
    capital stock of, or other equity interests in, WebMD or any
    WebMD Subsidiary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;All of the issued and outstanding shares or other
    ownership interests of each WebMD Subsidiary are duly
    authorized, validly issued, fully paid and nonassessable, and
    each such share or other ownership interest is owned by WebMD or
    another WebMD Subsidiary free and clear of all Encumbrances.
    There are no options, warrants or other rights, agreements,
    arrangements or commitments of any character relating to the
    issued or unissued capital stock of any WebMD Subsidiary or
    obligating any WebMD Subsidiary to issue or sell any shares of
    capital stock of, or other equity interests in, any WebMD
    Subsidiary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;The shares of WebMD Common Stock to be issued pursuant
    to the Merger in accordance with Article&#160;III (i)&#160;will
    be duly authorized, validly issued, fully paid and
    non-assessable and not subject to preemptive rights created by
    statute, WebMD&#146;s Restated Certificate of Incorporation or
    Amended and Restated Bylaws or any agreement to which WebMD is a
    party or is bound and (ii)&#160;will, when issued, be registered
    under the Securities Act and the Exchange Act and registered or
    exempt from registration under applicable Blue Sky Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.03&#160;&#160;<I><U>Authority
    Relative to This Agreement</U>.</I>&#160;&#160;WebMD has all
    necessary corporate power and authority to execute and deliver
    this Agreement, to perform its obligations hereunder and to
    consummate the Transactions. The execution and delivery of this
    Agreement by WebMD and the consummation by WebMD of the
    Transactions have been duly and validly authorized by all
    necessary corporate action, and no other
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    corporate proceedings on the part of WebMD are necessary to
    authorize this Agreement or to consummate the Transactions
    (other than the adoption of this Agreement and the approval of
    the Share Issuance by the stockholders of WebMD and the filing
    of the Certificate of Merger as contemplated by
    Section&#160;2.02). This Agreement has been duly and validly
    executed and delivered by WebMD and, assuming the due
    authorization, execution and delivery by HLTH, constitutes a
    legal, valid and binding obligation of WebMD, enforceable
    against WebMD in accordance with its terms, subject to the
    effect of any applicable bankruptcy, insolvency (including all
    laws relating to fraudulent transfers), reorganization,
    moratorium or similar laws affecting creditors&#146; rights
    generally and subject to the effect of general principles of
    equity (regardless of whether considered in a proceeding at law
    or in equity).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.04&#160;&#160;<I><U>No
    Conflict; Required Filings and Consents</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The execution and delivery of this Agreement by WebMD
    do not, and the performance of this Agreement by WebMD will not,
    (i)&#160;conflict with or violate the certificate of
    incorporation or bylaws or any equivalent organizational
    documents of WebMD or any WebMD Subsidiary, (ii)&#160;assuming
    that all Governmental Approvals and other actions described in
    Section&#160;5.04(b) have been obtained and all filings and
    notifications described in Section&#160;5.04(b) have been made,
    conflict with or violate any Law applicable to WebMD or any
    WebMD Subsidiary or by which any property or asset of WebMD or
    any WebMD Subsidiary is bound or affected, or (iii)&#160;result
    in any breach of or constitute a Default (or an event which,
    with notice or lapse of time or both, would become a Default)
    under, any Contract to which WebMD or any WebMD Subsidiary is a
    party or by which WebMD or any WebMD Subsidiary or any of their
    assets or properties is bound or affected, except, with respect
    to clauses&#160;(ii) and (iii), for any such Defaults which
    could not reasonably be expected, individually or in the
    aggregate, to prevent or materially delay consummation of the
    Transactions or otherwise prevent or materially delay WebMD from
    performing its obligations under this Agreement and could not
    reasonably be expected, individually or in the aggregate, to
    have a WebMD Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The execution and delivery of this Agreement by WebMD
    do not, and the performance of this Agreement by WebMD will not,
    require any Governmental Approval, or filing with or
    notification to any Governmental Authority, except (i)&#160;for
    applicable requirements, if any, of the Exchange Act, Blue Sky
    Laws and state takeover laws and filing and recordation of
    appropriate merger documents as required the DGCL, and
    (ii)&#160;where the failure to obtain such Governmental
    Approval, or to make such filings or notifications, could not
    reasonably be expected, individually or in the aggregate, to
    prevent or materially delay consummation of the Transactions, or
    otherwise prevent or materially delay WebMD from performing its
    obligations under this Agreement, and could not reasonably be
    expected, individually or in the aggregate, to have a WebMD
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.05&#160;&#160;<I><U>SEC
    Filings; Financial Statement</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;WebMD has filed all forms, reports and documents
    required to be filed by it with the SEC since December&#160;31,
    2008 (collectively, &#147;<U>WebMD SEC Reports</U>&#148;). As of
    their respective dates, or, if amended or superseded by a
    subsequent filing made prior to the date hereof, as of the date
    of the last such amendment or superseding filing prior to the
    date hereof, the WebMD SEC Reports filed prior to the date of
    this Agreement complied, and the WebMD SEC Reports filed
    subsequent to the date of this Agreement will comply, in all
    material respects with the requirements of the Securities Act
    and the Exchange Act, as the case may be, and the applicable
    rules and regulations promulgated thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;Each of the consolidated financial statements
    (including, in each case, any notes thereto) contained in the
    WebMD SEC Reports was prepared in accordance with GAAP applied
    on a consistent basis throughout the periods indicated (except
    as may be indicated in the notes thereto or, in the case of
    unaudited statements, as permitted by
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    of the SEC) and each fairly presents, in all material respects,
    the consolidated financial position, results of operations and
    cash flows of WebMD and its consolidated Subsidiaries as of the
    respective dates thereof and for the respective periods
    indicated therein, except as otherwise noted therein (subject,
    in the case of unaudited statements, to normal and recurring
    year-end adjustments which, individually or in the aggregate,
    have not had, and could not reasonably be expected to have, a
    WebMD Material Adverse Effect).
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Except as and to the extent reflected and reserved
    against in the consolidated balance sheet of WebMD and the
    consolidated WebMD Subsidiaries as of March&#160;31, 2009
    (including the notes thereto) included in the Filed WebMD SEC
    Documents, neither WebMD nor any WebMD Subsidiary has incurred
    any liability or obligation that would be required to be
    reflected on a balance sheet (or the notes thereto) prepared in
    accordance with GAAP, except for (i)&#160;liabilities or
    obligations incurred in connection with the Transactions
    contemplated by this Agreement, (ii)&#160;liabilities and
    obligations incurred in the Ordinary Course since March&#160;31,
    2009, (iii)&#160;liabilities, obligations and Indebtedness
    incurred in connection with the Little Blue Book Divestiture and
    (iv)&#160;liabilities which are not, individually or in the
    aggregate, material to WebMD and the WebMD Subsidiaries taken as
    a whole and could not, individually or in the aggregate,
    reasonably be expected to prevent or materially delay
    consummation of the Transactions or otherwise prevent or
    materially delay WebMD from performing its obligations under
    this Agreement and could not reasonably be expected,
    individually or in the aggregate, to have a WebMD Material
    Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.06&#160;&#160;<I><U>Absence
    of WebMD Material Adverse Effect</U>.</I>&#160;&#160;Since
    March&#160;31, 2009 through the date of this Agreement, except
    as expressly contemplated by this Agreement, there has not been
    any WebMD Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.07&#160;&#160;<I><U>Absence
    of Litigation</U>.</I>&#160;&#160;As of the date of this
    Agreement, there is no Action pending or, to the Knowledge of
    WebMD, threatened against WebMD or any WebMD Subsidiary, or any
    property or asset of WebMD or any WebMD Subsidiary, before any
    Governmental Authority that seeks to materially delay or prevent
    the consummation of the Transactions. Neither WebMD nor any
    WebMD Subsidiary nor any material property or asset of WebMD or
    any WebMD Subsidiary is subject to any Governmental Order that
    could reasonably be expected, individually or in the aggregate,
    to prevent or materially delay consummation of the Transactions
    or otherwise prevent or materially delay WebMD from performing
    its obligations under this Agreement or could reasonably be
    expected, in the individual or the aggregate, to have a WebMD
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.08&#160;&#160;<I><U>Board
    Approval; Vote Required</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The WebMD Board, upon the unanimous recommendation of
    the Special Committee, at a meeting duly called and held
    pursuant to the DGCL and WebMD&#146;s organizational documents,
    has adopted resolutions which were not subsequently rescinded or
    modified in any way (i)&#160;approving and declaring advisable
    this Agreement, the Merger and the other Transactions,
    (ii)&#160;declaring that it is in the best interests of the
    holders of Outstanding WebMD Capital Stock other than HLTH and
    the officers and directors of HLTH, WebMD and their respective
    affiliates that WebMD enter into this Agreement and consummate
    the Transactions, including the Share Issuance,
    (iii)&#160;directing that the adoption of this Agreement,
    including the approval of the Share Issuance be submitted to a
    vote at a meeting of the stockholders of WebMD and
    (iv)&#160;recommending that the stockholders of WebMD adopt this
    Agreement and approve the Share Issuance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;The only votes of the holders of any class or series of
    capital stock of WebMD necessary to adopt this Agreement and
    approve the Transactions is the affirmative vote of the holders
    of a majority of the voting power of the outstanding shares of
    Outstanding WebMD Capital Stock in favor thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.09&#160;&#160;<I><U>Ownership
    of HLTH Capital Stock</U>.</I>&#160;&#160;As of the date of this
    Agreement, WebMD is not the Beneficial Owner of any shares of
    capital stock of HLTH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.10&#160;&#160;<I><U>Opinion
    of Financial Advisor</U>.</I>&#160;&#160;The Special Committee
    has received the written opinion of Morgan Joseph&#160;&#038;
    Co. Inc., dated the date of this Agreement, to the effect that,
    as of such date, the consideration to be paid in the Merger by
    WebMD is fair, from a financial point of view, to the holders of
    Outstanding WebMD Capital Stock other than HLTH and the officers
    and directors of HLTH, WebMD, and their respective affiliates, a
    copy of which opinion has been delivered to HLTH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.11&#160;&#160;<I><U>Joint
    Proxy Statement/Prospectus</U>.</I>&#160;&#160;The information
    supplied by WebMD for inclusion in the Joint Proxy
    Statement/Prospectus will not, at (i)&#160;the time the
    Registration Statement is declared effective, (ii)&#160;the time
    the Joint Proxy Statement/Prospectus (or any amendment thereof
    or supplement thereto) is first mailed to the stockholders of
    HLTH and WebMD, (iii)&#160;the time of each of the HLTH
    Stockholders&#146; Meeting and the WebMD Stockholders&#146;
    Meeting and (iv)&#160;the Effective Time, contain any untrue
    statement of a
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    material fact or fail to state any material fact required to be
    stated therein or necessary in order to make the statements
    therein, in light of the circumstances under which they were
    made, not misleading.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>5.12&#160;&#160;<I><U>Brokers</U>.</I>&#160;&#160;No
    broker, finder or investment banker (other than Morgan
    Joseph&#160;&#038; Co. Inc.) is entitled to any brokerage,
    finder&#146;s or other fee or commission in connection with the
    Transactions based upon arrangements made by or on behalf of
    WebMD. WebMD has heretofore furnished to HLTH a complete and
    correct copy of all agreements between WebMD and Morgan
    Joseph&#160;&#038; Co. Inc. pursuant to which such firm would be
    entitled to any payment relating to the Transactions.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VI<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">CONDUCT OF
    BUSINESS PENDING THE MERGER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.01&#160;&#160;<I><U>Conduct
    of Business by HLTH Pending the Merger</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;HLTH agrees that, between the date of this Agreement
    and the Effective Time, except as set forth in Section&#160;6.01
    of the HLTH Disclosure Schedule, or as expressly contemplated by
    any other provision of this Agreement, unless WebMD shall
    otherwise consent (with the approval of the Special Committee)
    in writing (which consent shall not be unreasonably withheld or
    delayed):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;the businesses of HLTH (excluding the business of
    WebMD) and each HLTH Subsidiary shall be conducted in the
    Ordinary Course;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;HLTH shall use commercially reasonable efforts to
    preserve substantially intact the business organization of HLTH
    (excluding the business organization of WebMD) and each HLTH
    Subsidiary, to keep available the services of the current
    officers, employees and consultants of HLTH and each HLTH
    Subsidiary and to preserve the current relationships of HLTH and
    each HLTH Subsidiary with customers, suppliers and other Persons
    with which HLTH or any HLTH Subsidiary has significant business
    relations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;By way of amplification and not limitation, except as
    expressly contemplated by any other provision of this Agreement
    or as set forth in Section&#160;6.01 of the HLTH Disclosure
    Schedule, without the prior written consent (with the approval
    of the Special Committee) of WebMD (which consent shall not be
    unreasonably withheld or delayed), neither HLTH nor any HLTH
    Subsidiary, between the date of this Agreement and the Effective
    Time, will:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;amend or otherwise change its certificate of
    incorporation or bylaws, or equivalent organizational documents;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;issue, grant, sell, or redeem any capital stock or
    other ownership interests (other than in connection with the
    Merger or the exercise of a HLTH Stock Option or warrants of
    HLTH or pursuant to the conversion of the Convertible Notes) (or
    any securities convertible into, exchangeable or exercisable for
    or otherwise linked to the value of the same) or any bonds or
    other securities;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;declare, set aside, make or pay any dividend or other
    distribution, payable in cash, stock, property or otherwise,
    with respect to any of its capital stock, except for dividends
    by any direct or indirect wholly owned HLTH Subsidiary to HLTH
    or any other wholly owned HLTH Subsidiary;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;reclassify, combine, split, subdivide or redeem,
    purchase or otherwise acquire, directly or indirectly, any of
    its capital stock or other securities;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;acquire (including by merger, consolidation, or
    acquisition of stock or assets or any other business
    combination) any Person, business or any division thereof;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vi)&#160;make any material loan, advance, capital contribution
    to, or any investment in, any Person (other than a Subsidiary)
    except in the Ordinary Course;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vii)&#160;create or permit any Encumbrance (other than
    Permitted Encumbrances) on any asset or property except in the
    Ordinary Course;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (viii)&#160;incur, assume or otherwise become liable for any
    material Indebtedness other than trade payables in the Ordinary
    Course;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ix)&#160;modify the compensation or bonuses payable or to
    become payable or the benefits provided to its directors or
    Designated Employees, except for changes in the Ordinary Course
    (which shall include modifications or bonuses due to promotions
    and normal periodic performance reviews), or grant or modify any
    severance or termination pay to, or enter into or modify any
    vesting, employment, change of control, consulting or severance
    arrangement with, any director or Designated Employees, or
    establish, adopt, enter into or modify any HLTH Plan other than
    as expressly contemplated by this Agreement or as required by
    Law;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (x)&#160;make or rescind any material Tax election or settle or
    compromise any material Tax liability;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xi)&#160;change independent accountants or make any material
    change in any accounting methods, principles or practices (other
    than changes required by reason of a change in GAAP);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xii)&#160;other than in the Ordinary Course, fail to pay when
    due any material liability, except with respect to any such
    liability being contested in good faith;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xiii)&#160;permit any material insurance policy naming HLTH or
    a HLTH Subsidiary as a beneficiary or a loss payee to be
    cancelled or terminated (without replacing such policy with a
    substantially similar policy) or fail to pay any insurance
    premium in respect of any such policy (or replacement) when due;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xiv)&#160;adopt a plan of complete or partial liquidation,
    dissolution, restructuring, or recapitalization relating to HLTH
    that would materially and adversely affect the value
    thereof;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xv)&#160;enter into any Contract with respect to any of the
    foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Notwithstanding anything contained herein to the
    contrary, WebMD hereby acknowledges and agrees that
    (i)&#160;HLTH is contemplating the Porex Divestiture and
    (ii)&#160;subject to Article&#160;VIII, HLTH may enter into one
    or more agreements providing for, and consummate a transaction
    with respect to, the Porex Divestiture, in each case without the
    consent of WebMD, on such terms as are determined by HLTH in its
    discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>6.02&#160;&#160;<I><U>Conduct
    of Business by WebMD Pending the Merger</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;WebMD agrees that, between the date of this Agreement
    and the Effective Time, except as set forth in Section&#160;6.02
    of the WebMD Disclosure Schedule or as expressly contemplated by
    any other provision of this Agreement, unless HLTH shall
    otherwise consent, (which consent shall not be unreasonably
    withheld or delayed) in writing:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;the businesses of WebMD and each WebMD Subsidiary shall
    be conducted in the Ordinary Course;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;WebMD shall use commercially reasonable efforts to
    preserve substantially intact the business organization of WebMD
    and each WebMD Subsidiary, to keep available the services of the
    current officers, employees and consultants of WebMD and each
    WebMD Subsidiary and to preserve the current relationships of
    WebMD and each WebMD Subsidiary with customers, suppliers and
    other Persons with which WebMD or any WebMD Subsidiary has
    significant business relations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;By way of amplification and not limitation, except as
    expressly contemplated by any other provision of this Agreement
    or as set forth in Section&#160;6.02 of the WebMD Disclosure
    Schedule, without the prior written consent of HLTH (which
    consent shall not be unreasonably withheld or delayed) neither
    WebMD nor any WebMD Subsidiary, between the date of this
    Agreement and the Effective Time, will:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;amend or otherwise change its certificate of
    incorporation or bylaws, or equivalent organizational documents
    except as contemplated pursuant to Section&#160;2.04 of this
    Agreement;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;issue, grant, sell, or redeem any capital stock or
    other ownership interests (other than in connection with the
    Merger or the exercise of a stock option or any securities
    convertible into, exchangeable or exercisable for or otherwise
    linked to the value of the same) or any bonds or other
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    securities (<U>provided</U>, <U>however</U>, that WebMD may make
    grants, in the Ordinary Course, of stock options or restricted
    stock under WebMD&#146;s Amended and Restated 2005 Long-Term
    Incentive Plan);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;declare, set aside, make or pay any dividend or other
    distribution, payable in cash, stock, property or otherwise,
    with respect to any of its capital stock, except for dividends
    by any direct or indirect wholly owned Subsidiary of WebMD to
    WebMD or any other wholly owned Subsidiary of WebMD;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;reclassify, combine, split, subdivide or redeem,
    purchase or otherwise acquire, directly or indirectly, any of
    its capital stock or other securities;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;acquire (including by merger, consolidation, or
    acquisition of stock or assets or any other business
    combination) any Person, business or any division thereof;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vi)&#160;make any material loan, advance, capital contribution
    to, or any investment in, any Person (other than a Subsidiary)
    except in the Ordinary Course;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vii)&#160;create or permit any Encumbrance (other than
    Permitted Encumbrances) on any asset or property except in the
    Ordinary Course;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (viii)&#160;incur, assume or otherwise become liable for any
    material Indebtedness other than trade payables in the Ordinary
    Course;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ix)&#160;make or rescind any material Tax election or settle or
    compromise any material Tax liability;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (x)&#160;change independent accountants or make any material
    change in any accounting methods, principles or practices (other
    than changes required by reason of a change in GAAP);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xi)&#160;other than in the Ordinary Course, fail to pay when
    due any material liability, except with respect to any such
    liability being contested in good faith;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xii)&#160;permit any material insurance policy naming WebMD or
    a WebMD Subsidiary as a beneficiary or a loss payee to be
    cancelled or terminated (without replacing such policy with a
    substantially similar policy) or fail to pay any insurance
    premium in respect of any such policy (or replacement) when due;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xiii)&#160;adopt a plan of complete or partial liquidation,
    dissolution, restructuring, or recapitalization that would
    materially and adversely affect the value thereof;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (xiv)&#160;enter into any Contract with respect to any of the
    foregoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Notwithstanding anything contained herein to the
    contrary, HLTH hereby acknowledges and agrees that
    (i)&#160;WebMD is contemplating the Little Blue Book Divestiture
    and (ii)&#160;subject to Article&#160;VIII, WebMD may enter into
    one or more agreements providing for, and consummate a
    transaction with respect to, the Little Blue Book Divestiture,
    in each case without the consent of HLTH, on such terms as are
    determined by WebMD in its discretion.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VII<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ADDITIONAL
    AGREEMENTS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.01&#160;&#160;<I><U>Registration
    Statement and Other SEC Filings</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;As soon as reasonably practicable after the execution
    of this Agreement, (i)&#160;HLTH and WebMD shall prepare and
    file with the SEC a preliminary joint proxy statement relating
    to the HLTH Stockholders&#146; Meeting and the WebMD
    Stockholders&#146; Meeting and (ii)&#160;HLTH and WebMD shall
    prepare and file with the SEC a Registration Statement on
    <FONT style="white-space: nowrap">Form&#160;S-4</FONT>
    (the &#147;<U>Registration Statement</U>&#148;) in connection
    with the registration under the Securities Act of WebMD Common
    Stock issuable in the Merger. The joint proxy statement
    furnished to HLTH&#146;s stockholders in connection with the
    HLTH Stockholders&#146; Meeting and to WebMD&#146;s stockholders
    in connection with the WebMD Stockholders&#146; Meeting shall be
    included as part of the prospectus (the &#147;<U>Joint Proxy
    Statement/Prospectus</U>&#148;) forming part of the Registration
    Statement. Each party hereto shall, and shall
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    cause their respective counsel, accountants and other advisors
    to, use reasonable best efforts to cooperate with each other in
    connection with the preparation and filing of the preliminary
    joint proxy statement, the Joint Proxy Statement/Prospectus and
    the Registration Statement. Each party hereto shall, and shall
    cause their respective counsel, accountants and other advisors
    to, use reasonable best efforts to respond to any comments of
    the SEC, to cause the Registration Statement to be declared
    effective under the Securities Act as soon as reasonably
    practicable after such filing and to continue to be effective as
    of the Effective Time, to take any necessary action and obtain
    all necessary state securities law or &#147;Blue Sky&#148;
    permits and approvals required to carry out the transactions
    contemplated by this Agreement in connection with the
    Registration Statement and to cause the Joint Proxy
    Statement/Prospectus to be mailed to HLTH&#146;s and
    WebMD&#146;s stockholders at the earliest practicable time after
    the Registration Statement is declared effective by the SEC,
    including providing all information about itself to the other
    party as may be reasonably requested in connection with any such
    action.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;Each party shall notify the other party and the Special
    Committee promptly of the receipt of any comments of the SEC or
    its staff and of any request by the SEC or its staff or any
    other Governmental Authority for amendments or supplements to
    the preliminary joint proxy statement, the Joint Proxy
    <FONT style="white-space: nowrap">Statement/Prospectus,</FONT>
    the Registration Statement or any other related filings or for
    additional information related thereto, and shall supply the
    other party and the Special Committee with copies of all
    correspondence between it and any of its Representatives, on the
    one hand, and the SEC or its staff or any other Governmental
    Authority, on the other hand, with respect to the preliminary
    joint proxy statement, the Joint Proxy Statement/Prospectus, the
    Registration Statement, the Merger or any other filings relating
    thereto. The Joint Proxy Statement/Prospectus, the Registration
    Statement and such other filings shall comply in all material
    respects with all applicable requirements of Law. If at any time
    prior to the Effective Time, any event occurs or either party
    becomes aware of any information relating to the other party or
    its Subsidiaries or any of their respective officers or
    directors or Affiliates that should be described in an amendment
    or supplement to the Joint Proxy Statement/Prospectus, the
    Registration Statement or any other related filings, the
    applicable party shall inform the other party and the Special
    Committee promptly after becoming aware of such event or
    information and cooperate in filing with the SEC or its staff or
    any other Governmental Authority,
    <FONT style="white-space: nowrap">and/or</FONT>
    mailing to stockholders of HLTH or WebMD, as applicable, such
    amendment or supplement. The parties shall cooperate and provide
    each other and the Special Committee with a reasonable
    opportunity to review and comment on the preliminary joint proxy
    statement, the Joint Proxy Statement/Prospectus, the
    Registration Statement, any related filings or amendment or
    supplement thereto and any responses or communications to the
    SEC staff or other Governmental Authority in connection
    therewith; <U>provided</U> <U>that</U>, with respect to
    documents filed by HLTH or WebMD that are incorporated by
    reference in the Joint Proxy Statement/Prospectus, or the
    Registration Statement, this right of review and comment shall
    apply only with respect to information relating to the other
    party or its business, financial condition or results of
    operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;WebMD and HLTH each shall advise the other, promptly
    after receiving notice thereof, of the time when the
    Registration Statement has become effective or any supplement or
    amendment has been filed, of the issuance of any stop order, of
    the suspension of the qualification of WebMD Common Stock
    issuable in connection with the Merger for offering or sale in
    any jurisdiction, or of any request by the SEC for amendment of
    the Joint Proxy Statement/Prospectus or comments thereon and
    responses thereto or requests by the SEC for additional
    information.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.02&#160;&#160;<I><U>Stockholders&#146;
    Meetings</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;HLTH shall, in accordance with the DGCL, Delaware
    case-law interpreting the DGCL and HLTH&#146;s organizational
    documents, duly call, give notice of and hold a meeting of
    HLTH&#146;s stockholders as promptly as practicable for the
    purpose of voting upon the adoption of this Agreement (the
    &#147;<U>HLTH Stockholders&#146; Meeting</U>&#148;). WebMD
    shall, in accordance with the DGCL, Delaware case-law
    interpreting the DGCL and WebMD&#146;s organizational documents,
    duly call, give notice of and hold a meeting of WebMD&#146;s
    stockholders as promptly as practicable for the purpose of
    voting upon the adoption of this Agreement, including the
    approval of the Share Issuance (the &#147;<U>WebMD
    Stockholders&#146; Meeting</U>&#148;). Each of HLTH and WebMD
    shall use its reasonable best efforts to hold the
    Stockholders&#146; Meetings on the same day as soon as
    practicable after the date on which the Registration Statement
    becomes effective. Each of HLTH and WebMD shall include in the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proxy Statement the recommendation of their respective boards of
    directors that stockholders of each entity vote in favor of the
    approval of the Transactions and the adoption of this Agreement.
    Each of HLTH and WebMD shall use its reasonable best efforts to
    solicit from its stockholders proxies in favor of the adoption
    of this Agreement and the approval of the Transactions, as
    applicable, and shall take all other action necessary or
    advisable to secure the required vote or consent of its
    stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;Subject to Article&#160;IX, HLTH agrees to vote, or
    cause to be voted, all of the shares of (i)&#160;WebMD
    Class&#160;A Common Stock and (ii)&#160;WebMD Class&#160;B
    Common Stock then beneficially owned by it or a HLTH Subsidiary
    in favor of the approval of the Transactions and the adoption of
    this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;Subject to Article&#160;IX, the obligation of HLTH and
    WebMD to call, give notice of, convene and hold the HLTH
    Stockholders&#146; Meeting and the WebMD Stockholders&#146;
    Meeting, as applicable, and to hold a vote of the HLTH Common
    Stock holders and the Outstanding WebMD Capital Stock holders on
    this Agreement shall not be limited or otherwise affected by a
    Competing Transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.03&#160;&#160;<I><U>Access
    to Information</U>.</I>&#160;&#160;Except as required pursuant
    to any confidentiality agreement or similar agreement or
    arrangement to which HLTH or WebMD or any of their respective
    Subsidiaries is a party or pursuant to applicable Law, from the
    date of this Agreement until the Effective Time, HLTH and WebMD
    shall (and shall cause their respective Subsidiaries to):
    (i)&#160;provide to the other party and the Special Committee
    (and their Representatives) access at reasonable times upon
    prior notice to the officers, employees, agents, properties,
    offices and other facilities of such party and its Subsidiaries
    and to the books and records thereof; and (ii)&#160;furnish
    promptly to the other party and the Special Committee (and their
    Representatives) such information concerning the business,
    properties, contracts, assets, liabilities, personnel and other
    aspects of such party and its Subsidiaries as reasonably
    requested.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.04&#160;&#160;<I><U>Directors&#146;
    and Officers&#146; Insurance</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;WebMD and HLTH shall cooperate to maintain
    officers&#146; and directors&#146; liability insurance in
    respect of acts or omissions occurring prior to the Effective
    Time covering those persons who are currently covered on the
    date of this Agreement by HLTH&#146;s directors&#146; and
    officers&#146; liability insurance policy or who become covered
    prior to the Effective Time on terms with respect to coverage
    and amount no less favorable than those in the current
    directors&#146; and officers&#146; liability insurance policy
    maintained by HLTH in effect on the date hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The WebMD Charter Amendment and the bylaws of the
    Surviving Corporation shall not be amended, modified or repealed
    for a period of six years from the Effective Time in a manner
    that would adversely affect the rights with respect to
    indemnification, advancement of expenses and exculpation of
    individuals who, at or prior to the Effective Time, were
    officers or directors of HLTH, unless such amendment,
    modification or repeal is required by applicable Law after the
    Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.05&#160;&#160;<I><U>Further
    Action; Reasonable Best Efforts</U>.</I>&#160;&#160;Upon the
    terms and subject to the conditions of this Agreement, each of
    the parties hereto shall use its reasonable best efforts to
    take, or cause to be taken, all appropriate action, and to do,
    or cause to be done, all things necessary, proper or advisable
    under applicable Law or otherwise to consummate and make
    effective the Transactions, including using its reasonable best
    efforts to obtain all permits, consents, approvals,
    authorizations, qualifications and orders of Governmental
    Authorities and parties to Contracts with HLTH or WebMD or their
    Subsidiaries as are necessary for the consummation of the
    Transactions and to fulfill the conditions to the Merger. In
    case, at any time after the Effective Time, any further action
    is necessary or desirable to carry out the purposes of this
    Agreement, the proper officers and directors of each party to
    this Agreement shall use their reasonable best efforts to take
    all such action.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.06&#160;&#160;<I><U>Plan
    of Reorganization</U>.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;This Agreement is intended to constitute a &#147;plan
    of reorganization&#148; within the meaning of
    <FONT style="white-space: nowrap">Section&#160;1.368-2(g)</FONT>
    of the income tax regulations promulgated under the Code. From
    and after the date of this Agreement and until the Effective
    Time, each party hereto shall use its reasonable best efforts to
    cause the Merger to qualify, and will not knowingly take any
    action, cause any action to be taken, fail to take any action
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    or cause any action to fail to be taken which action or failure
    to act could prevent the Merger from qualifying as a
    reorganization within the meaning of Section&#160;368(a) of the
    Code. Following the Effective Time, neither WebMD nor any of its
    Affiliates shall knowingly take any action, cause any action to
    be taken, fail to take any action or cause any action to fail to
    be taken, which action or failure to act could cause the Merger
    to fail to qualify as a reorganization within the meaning of
    Section&#160;368(a) of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;As of the date hereof, HLTH does not know of any reason
    (i)&#160;why it would not be able to deliver to counsel to HLTH
    and WebMD, at the date of the legal opinions referred to below,
    certificates substantially in compliance with IRS published
    advance ruling guidelines, with customary exceptions and
    modifications thereto, to enable such firms to deliver the legal
    opinions contemplated by Section&#160;8.02(e) and
    Section&#160;8.03(e), and HLTH hereby agrees to deliver such
    certificates effective as of the date of such opinions or
    (ii)&#160;why counsel to HLTH and WebMD would not be able to
    deliver the opinions required by Section&#160;8.02(e) and
    Section&#160;8.03(e).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;As of the date hereof, WebMD does not know of any
    reason (i)&#160;why it would not be able to deliver to counsel
    to HLTH and WebMD, at the date of the legal opinions referred to
    below, certificates substantially in compliance with IRS
    published advance ruling guidelines, with customary exceptions
    and modifications thereto, to enable such firms to deliver the
    legal opinions contemplated by Section&#160;8.02(e) and
    Section&#160;8.03(e), and WebMD hereby agrees to deliver such
    certificates effective as of the date of such opinions or
    (ii)&#160;why counsel to HLTH and WebMD would not be able to
    deliver the opinions required by Section&#160;8.02(e) and
    Section&#160;8.03(e).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.07&#160;&#160;<I><U>Nasdaq
    Quotation</U>.</I>&#160;&#160;WebMD shall use its reasonable
    best efforts to cause the shares of WebMD Common Stock issuable
    in the Merger and pursuant to the HLTH Stock Options assumed by
    WebMD to be approved for listing on Nasdaq, subject to official
    notice of issuance to Nasdaq, as promptly as practicable after
    the date hereof and in any event prior to the Closing Date, and
    HLTH shall cooperate with WebMD with respect to such approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.08&#160;&#160;<I><U>Public
    Announcements</U>.</I>&#160;&#160;The initial press release
    relating to this Agreement shall be a joint press release the
    text of which has been agreed to by each of WebMD (with the
    approval of the Special Committee) and HLTH. Thereafter, unless
    otherwise required by applicable Law or the requirements of
    Nasdaq, each of WebMD and HLTH shall each use its reasonable
    best efforts to consult with each other before issuing any press
    release or otherwise making any public statements with respect
    to this Agreement or any of the Transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.09&#160;&#160;<I><U>Assumption
    of Existing Indentures</U>.</I>&#160;&#160;WebMD acknowledges
    and agrees that, as of the Effective Time, WebMD, as the
    Surviving Corporation, shall become the successor obligor to
    HLTH under the Existing Indentures, and shall assume and honor
    the obligations of HLTH thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>7.10&#160;&#160;<I><U>Notification
    of Certain Matters</U>.</I>&#160;&#160;Between the date hereof
    and the Effective Time, each party shall give prompt notice in
    writing to the other party of: (i)&#160;the occurrence or
    failure to occur, or the impending or threatened occurrence or
    failure to occur, of any event or circumstance which occurrence
    or failure to occur could reasonably be expected to cause any of
    its representations or warranties in this Agreement to be untrue
    or inaccurate in any material respect at any time from the date
    hereof through the Effective Time; (ii)&#160;the occurrence or
    failure to occur, or the impending, alleged or threatened
    occurrence or failure to occur, of any event or circumstance
    which occurrence or failure to occur could reasonably be
    expected to cause any condition, covenant or agreement contained
    in this Agreement to fail to be complied with or satisfied; and
    (iii)&#160;any notice or other communication from any Person
    alleging that the Consent of such Person is or may be required
    in connection with the Transactions or that the Transactions
    otherwise constitute a Default under any Contract that is
    material to such party; provided, that the delivery of any
    notice pursuant to this Section&#160;7.10 will not limit or
    otherwise affect the remedies available to the party receiving
    such notice.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VIII<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">CONDITIONS
    TO THE MERGER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.01&#160;&#160;<I><U>Conditions
    to the Obligations of Each Party</U>.</I>&#160;&#160;The
    obligations of HLTH and WebMD to consummate the Merger are
    subject to the satisfaction or waiver (where permissible) of the
    following conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Registration Statement</U>.</I>&#160;&#160;The
    Registration Statement shall have been declared effective by the
    SEC under the Securities Act and no stop order suspending the
    effectiveness of the Registration Statement shall have been
    issued by the SEC and no proceeding for that purpose shall have
    been initiated by the SEC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>HLTH Stockholder
    Adoption</U>.</I>&#160;&#160;This Agreement shall have been
    adopted by the stockholders of HLTH in accordance with the DGCL.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>WebMD Stockholder Adoption and
    Approval</U>.</I>&#160;&#160;This Agreement shall have been
    adopted, and the Transactions shall have been approved by the
    votes specified in Section&#160;5.08(b) hereof, in accordance
    with the DGCL and, in the case of the Share Issuance, the rules
    and regulations of Nasdaq.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;<I><U>No Order</U>.</I>&#160;&#160;No Governmental
    Authority shall have enacted, issued, promulgated, enforced or
    entered any Law or Governmental Order which is then in effect
    and has the effect of making the Merger illegal or otherwise
    prohibiting consummation of the Merger.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;<I><U>Nasdaq Quotation</U>.</I>&#160;&#160;The shares
    of WebMD Common Stock to be issued in the Merger shall have been
    authorized for quotation on Nasdaq, subject to official notice
    of issuance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.02&#160;&#160;<I><U>Conditions
    to the Obligations of WebMD</U>.</I>&#160;&#160;The obligations
    of WebMD to consummate the Merger are subject to the
    satisfaction or waiver (where permissible) of the following
    additional conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Representations and
    Warranties</U>.</I>&#160;&#160;The representations and
    warranties of HLTH contained in this Agreement shall be true and
    correct (without giving effect to any qualification or exception
    with respect to materiality or HLTH Material Adverse Effect or
    similar language set forth therein) as of the Effective Time, as
    though made on and as of such date (except to the extent
    expressly made as of an earlier date, in which case as of such
    earlier date), except where the failure to be so true and
    correct would not, individually or in the aggregate, have a HLTH
    Material Adverse Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Agreements and Covenants</U>.</I>&#160;&#160;HLTH
    shall have performed or complied with all agreements and
    covenants required by this Agreement to be performed or complied
    with by it on or prior to the Effective Time in all material
    respects.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Officer Certificate</U>.</I>&#160;&#160;HLTH
    shall have delivered to WebMD a certificate, dated the date of
    the Closing, signed by an executive officer of HLTH, certifying
    as to the satisfaction of the conditions specified in
    Sections&#160;8.02(a), 8.02(b) and 8.02(d).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;<I><U>Tax Opinion</U>.</I>&#160;&#160;WebMD shall have
    received the opinion of Cahill Gordon&#160;&#038; Reindel LLP,
    counsel to the Special Committee, based upon representations of
    WebMD and HLTH, and normal assumptions, to the effect that, for
    federal income tax purposes, the Merger will qualify as a
    reorganization within the meaning of Section&#160;368(a) of the
    Code and that each of WebMD and HLTH will be a party to the
    reorganization within the meaning of Section&#160;368(b) of the
    Code, which opinion shall not have been withdrawn or modified in
    any material respect. The issuance of such opinion shall be
    conditioned on receipt by Cahill Gordon&#160;&#038; Reindel LLP
    of representation letters from each of WebMD and HLTH as
    contemplated by Section&#160;7.06 of this Agreement. Each such
    representation letter shall be dated on or before the date of
    such opinion and shall not have been withdrawn or modified in
    any material respect as of the Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;<I><U>Material Adverse Effect</U>.</I>&#160;&#160;No
    HLTH Material Adverse Effect shall have occurred since the date
    of this Agreement.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>8.03&#160;&#160;<I><U>Conditions
    to the Obligations of HLTH</U>.</I>&#160;&#160;The obligations
    of HLTH to consummate the Merger are subject to the satisfaction
    or waiver (where permissible) of the following additional
    conditions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Representations and
    Warranties</U>.</I>&#160;&#160;The representations and
    warranties of WebMD contained in this Agreement shall be true
    and correct (without giving effect to any qualification or
    exception with respect to materiality or WebMD Material Adverse
    Effect or similar language set forth therein) as of the
    Effective Time, as though made on and as of such date (except to
    the extent expressly made as of an earlier date, in which case
    as of such earlier date), except where the failure of such
    representations to be so true and correct would not,
    individually or in the aggregate, have a WebMD Material Adverse
    Effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Agreements and
    Covenants</U>.</I>&#160;&#160;WebMD shall have performed or
    complied in all material respects with all agreements and
    covenants required by this Agreement to be performed or complied
    with by it on or prior to the Effective Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Officer Certificate</U>.</I>&#160;&#160;WebMD
    shall have delivered to HLTH a certificate, dated the date of
    the Closing, signed by an executive officer of WebMD, certifying
    as to the satisfaction of the conditions specified in
    Sections&#160;8.03(a), 8.03(b) and 8.03(d).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;<I><U>Material Adverse Effect</U>.</I>&#160;&#160;No
    WebMD Material Adverse Effect shall have occurred since the date
    of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;<I><U>Tax Opinion</U>.</I>&#160;&#160;HLTH shall have
    received the opinion of Shearman&#160;&#038; Sterling LLP,
    counsel to HLTH, based upon representations of WebMD and HLTH,
    and normal assumptions, to the effect that, for federal income
    tax purposes, the Merger will qualify as a reorganization within
    the meaning of Section&#160;368(a) of the Code and that each of
    WebMD and HLTH will be a party to the reorganization within the
    meaning of Section&#160;368(b) of the Code, which opinion shall
    not have been withdrawn or modified in any material respect. The
    issuance of such opinion shall be conditioned on receipt by
    Shearman&#160;&#038; Sterling LLP of representation letters from
    each of WebMD and HLTH as contemplated in Section&#160;7.06 of
    this Agreement. Each such representation letter shall be dated
    on or before the date of such opinion and shall not have been
    withdrawn or modified in any material respect as of the
    Effective Time.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IX<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">TERMINATION,
    AMENDMENT AND WAIVER
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.01&#160;&#160;<I><U>Termination</U>.</I>&#160;&#160;This
    Agreement may be terminated and the Transactions may be
    abandoned at any time prior to the Effective Time,
    notwithstanding any requisite adoption of this Agreement and the
    Transactions by the stockholders of HLTH and WebMD, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;by mutual written consent of WebMD and HLTH duly
    authorized by the Boards of Directors of WebMD (with the
    approval of the Special Committee) and HLTH;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;by either WebMD (upon the approval of the Special
    Committee) or HLTH if the Effective Time shall not have occurred
    on or before the End Date; <U>provided</U>, <U>however</U>, that
    the right to terminate this Agreement under this
    Section&#160;9.01(b) shall not be available to any party whose
    failure to fulfill any obligation under this Agreement has been
    the cause of, or resulted in, the failure of the Effective Time
    to occur on or before such date;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;by either WebMD (upon the approval of the Special
    Committee) or HLTH if any Governmental Authority in the United
    States shall have enacted, issued, promulgated, enforced or
    entered any Law or Governmental Order (whether temporary,
    preliminary or permanent) which has become final and
    nonappealable and has the effect of making consummation of the
    Merger illegal or otherwise preventing or prohibiting
    consummation of the Merger;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;by WebMD (upon the approval of the Special Committee)
    if a Triggering Event with respect to HLTH shall have
    occurred;&#160;or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;by HLTH if a Triggering Event with respect to WebMD
    shall have occurred;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;by either WebMD (upon the approval of the Special
    Committee) or HLTH if the stockholders of HLTH shall fail to
    adopt this Agreement at the HLTH Stockholders&#146;
    Meeting;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;by either WebMD (upon the approval of the Special
    Committee) or HLTH if, at the WebMD Stockholders&#146; Meeting,
    this Agreement shall not have been adopted, or the Share
    Issuance shall not have been approved by the votes specified in
    Section&#160;5.08(b) hereof;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;by WebMD (upon the approval of the Special Committee)
    upon a breach of any representation, warranty, covenant or
    agreement on the part of HLTH set forth in this Agreement, or if
    any representation or warranty of HLTH shall have become untrue,
    in either case such that the condition set forth in
    Section&#160;8.02(a) or Section&#160;8.02(b) would not be
    satisfied (a &#147;<U>Terminating HLTH Breach</U>&#148;);
    <U>provided</U>, <U>however</U>, that, if such Terminating HLTH
    Breach is curable by HLTH, WebMD may not terminate this
    Agreement under this Section&#160;9.01(h) for so long as HLTH
    continues to exercise its best efforts to cure such breach,
    unless such breach is not cured within 15 Business Days after
    written notice of such breach is provided by WebMD to
    HLTH;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;by HLTH upon a breach of any representation, warranty,
    covenant or agreement on the part of WebMD set forth in this
    Agreement, or if any representation or warranty of WebMD shall
    have become untrue, in either case such that the condition set
    forth in Section&#160;8.03(a) or Section&#160;8.03(b) would not
    be satisfied (a &#147;<U>Terminating WebMD Breach</U>&#148;);
    <U>provided</U>, <U>however</U>, that, if such Terminating WebMD
    Breach is curable by WebMD, HLTH may not terminate this
    Agreement under this Section&#160;9.01(i) for so long as WebMD
    continues to exercise its best efforts to cure such breach,
    unless such breach is not cured within 15 Business Days after
    written notice of such breach is provided by HLTH to
    WebMD;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;by HLTH, upon the approval of the HLTH Board, if the
    HLTH Board determines, in its good faith judgment after
    consultation with independent legal counsel (which legal counsel
    may be HLTH&#146;s regularly engaged independent legal counsel),
    that it is required by its fiduciary duties under applicable Law
    to terminate this Agreement in order to enter into a definitive
    agreement with respect to a Superior Proposal;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (k)&#160;by WebMD, upon the approval of the Special Committee if
    the Special Committee determines, in its good faith judgment
    after consultation with its legal counsel, that it is required
    by its fiduciary duties under applicable Law to terminate this
    Agreement in order to enter into a definitive agreement with
    respect to a Superior Proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.02&#160;&#160;<I><U>Effect
    of Termination</U>.</I>&#160;&#160;In the event of the
    termination of this Agreement pursuant to Section&#160;9.01,
    this Agreement shall forthwith become void, and there shall be
    no liability under this Agreement on the part of any party
    hereto, except (a)&#160;as set forth in Section&#160;9.03 and
    (b)&#160;nothing herein shall relieve any party from liability
    or damages for any willful or intentional breach of any of its
    representations, warranties, covenants or agreements set forth
    in this Agreement prior to such termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.03&#160;&#160;<I><U>Fees
    and Expenses</U>.</I>&#160;&#160;All Expenses (as defined below)
    incurred by either party and the Special Committee in connection
    with this Agreement and the Transactions contemplated by this
    Agreement shall be paid by HLTH. &#147;Expenses&#148;, as used
    in this Agreement, shall include all reasonable
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    expenses (including, without limitation, all fees and expenses
    of counsel, accountants, investment bankers, experts and
    consultants to a party hereto (and the Special Committee) and
    its affiliates) incurred by a party or on its behalf in
    connection with or related to the authorization, preparation,
    negotiation, execution and performance of this Agreement, the
    preparation, printing, filing and mailing of the Registration
    Statement and the Joint Proxy Statement/Prospectus, the
    solicitation of stockholder approvals and all other matters
    related to the closing of the Merger and the other transactions
    contemplated by this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.04&#160;&#160;<I><U>Amendment</U>.</I>&#160;&#160;This
    Agreement may be amended by the parties hereto by action taken
    by or on behalf of their respective Boards of Directors (with
    the approval of the Special Committee, in the case of WebMD) at
    any time prior to the Effective Time; provided, however, that,
    after the adoption of this Agreement by the stockholders of
    HLTH, no amendment shall be made which under Law requires
    further
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    approval of the stockholders of HLTH or WebMD without such
    further approval. This Agreement may not be amended except by an
    instrument in writing signed by each of the parties hereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>9.05&#160;&#160;<I><U>Waiver</U>.</I>&#160;&#160;At
    any time prior to the Effective Time, either party hereto (with
    the approval of the Special Committee in the case of WebMD) may
    (a)&#160;extend the time for the performance of any obligation
    or other act of the other party, (b)&#160;waive any inaccuracy
    in the representations and warranties of the other party
    contained herein or in any document delivered pursuant hereto
    and (c)&#160;waive compliance with any agreement of the other
    party or any condition to its own obligations contained herein.
    Any such extension or waiver shall be valid if set forth in an
    instrument in writing signed by the party or parties to be bound
    thereby.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;X<BR>
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">GENERAL
    PROVISIONS
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.01&#160;&#160;<I><U>Non-Survival
    of Representations, Warranties, Covenants and
    Agreements</U>.</I>&#160;&#160;The representations, warranties,
    covenants and agreements in this Agreement and in any
    certificate delivered pursuant hereto shall terminate at the
    Effective Time or upon the termination of this Agreement
    pursuant to Section&#160;9.01, as the case may be, except that
    the agreements set forth in Articles&#160;II and&#160;III and
    Sections&#160;7.04 and 7.07 and this Article&#160;X shall
    survive the Effective Time, and except that the agreements set
    forth in Sections&#160;9.02 and 9.03 and this Article&#160;X
    shall survive the termination of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.02&#160;&#160;<I><U>Notices</U>.</I>&#160;&#160;All
    notices, requests, claims, demands and other communications
    hereunder shall be in writing and shall be given (and shall be
    deemed to have been duly given upon receipt) by delivery in
    person, by telecopy or email or by registered or certified mail
    (postage prepaid, return receipt requested) to the respective
    parties at the following addresses (or at such other address for
    a party as shall be specified in a notice given in accordance
    with this Section&#160;10.02):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    if to WebMD or the Surviving Corporation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WebMD Health Corp.<BR>
    111 Eighth Avenue<BR>
    New York, New York 10011<BR>
    Attention: General Counsel<BR>
    Facsimile:
    <FONT style="white-space: nowrap">(212)&#160;624-3773</FONT><BR>
    Email: dwamsley@webmd.net<BR>
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with a copy to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cahill Gordon&#160;&#038; Reindel LLP<BR>
    Eighty Pine Street<BR>
    New York, New York 10005<BR>
    Attention: William M. Hartnett<BR>
    Facsimile:
    <FONT style="white-space: nowrap">(212)&#160;378-2198</FONT><BR>
    Email: whartnett@cahill.com
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    if to HLTH:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HLTH Corporation<BR>
    River Drive Center Two<BR>
    699 River Drive<BR>
    Elmwood Park, New Jersey
    <FONT style="white-space: nowrap">07407-1371</FONT><BR>
    Attention: General Counsel<BR>
    Facsimile:
    <FONT style="white-space: nowrap">(201)&#160;703-3449</FONT><BR>
    Email: cmele@hlth.com
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with copies to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shearman&#160;&#038; Sterling LLP<BR>
    Broadgate West<BR>
    9 Appold Street<BR>
    London, EC2A 2AP<BR>
    United Kingdom<BR>
    Attention: Creighton O&#146;M. Condon<BR>
    Facsimile: +44 20 7655 5500<BR>
    Email: ccondon@shearman.com
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shearman&#160;&#038; Sterling LLP<BR>
    599 Lexington Avenue<BR>
    New York, New York 10022<BR>
    Attention: Robert M. Katz<BR>
    Facsimile:
    <FONT style="white-space: nowrap">(646)&#160;848-8008</FONT><BR>
    Email: rkatz@shearman.com
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.03&#160;&#160;<I><U>Severability</U>.</I>&#160;&#160;If
    any term or other provision of this Agreement is invalid,
    illegal or incapable of being enforced by any rule of Law or by
    public policy, all other conditions and provisions of this
    Agreement shall nevertheless remain in full force and effect so
    long as the economic or legal substance of the Transactions is
    not affected in any manner materially adverse to any party. Upon
    such determination that any term or other provision is invalid,
    illegal or incapable of being enforced, the parties hereto shall
    negotiate in good faith to modify this Agreement so as to effect
    the original intent of the parties as closely as possible in a
    mutually acceptable manner in order that the Transactions be
    consummated as originally contemplated to the fullest extent
    possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.04&#160;&#160;<I><U>Entire
    Agreement; Assignment</U>.</I>&#160;&#160;This Agreement
    (including the HLTH Disclosure Schedule and the WebMD Disclosure
    Schedule) constitutes the entire agreement between the parties
    with respect to the subject matter hereof and supersedes all
    prior agreements and undertakings, both written and oral,
    between the parties with respect to the subject matter hereof.
    This Agreement shall not be assigned (whether pursuant to a
    merger, by operation of law or otherwise).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.05&#160;&#160;<I><U>Parties
    in Interest</U>.</I>&#160;&#160;This Agreement shall be binding
    upon and inure solely to the benefit of each party hereto, and
    nothing in this Agreement, express or implied, is intended to or
    shall confer upon any other Person (including stockholders of
    either party) any right, benefit or remedy of any nature
    whatsoever under or by reason of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.06&#160;&#160;<I><U>Specific
    Performance</U>.</I>&#160;&#160;The parties hereto agree that
    irreparable damage would occur in the event any provision of
    this Agreement were not performed in accordance with the terms
    hereof and that the parties shall be entitled to specific
    performance of the terms hereof, in addition to any other remedy
    to which they are entitled at law or in equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.07&#160;&#160;<I><U>Governing
    Law; Jurisdiction</U>.</I>&#160;&#160;This Agreement and the
    legal relations between the parties shall be governed by, and
    construed in accordance with, the laws of the State of Delaware,
    without regard to the conflict of laws rules thereof. All
    actions and proceedings arising out of or relating to this
    Agreement shall be heard and determined exclusively in the Court
    of Chancery of the State of Delaware in and for New Castle
    County, Delaware. The parties hereto hereby (a)&#160;submit to
    the exclusive jurisdiction of any Delaware state or federal
    court for the purpose of any Action arising out of or relating
    to this Agreement brought by any party hereto, and
    (b)&#160;irrevocably waive, and agree not to assert by way of
    motion, defense, or otherwise, in any such Action, any claim
    that it is not subject personally to the jurisdiction of the
    above-named courts, that its property is exempt or immune from
    attachment or execution, that the Action is brought in an
    inconvenient forum, that the venue of the Action is improper, or
    that this Agreement or the Transactions may not be enforced in
    or by any of the above-named courts.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.08&#160;&#160;<I><U>Waiver
    of Jury Trial</U>.</I>&#160;&#160;Each of the parties hereto
    hereby waives to the fullest extent permitted by applicable Law
    any right it may have to a trial by jury with respect to any
    litigation directly or indirectly arising out of, under or in
    connection with this Agreement or the Transactions. Each of the
    parties hereto (a)&#160;certifies that no representative, agent
    or attorney of the other party has represented, expressly or
    otherwise, that such other party would not, in the event of
    litigation, seek to enforce that foregoing waiver and
    (b)&#160;acknowledges that it and the other party hereto have
    been induced to enter into this Agreement and the Transactions,
    as applicable, by, among other things, the mutual waivers and
    certifications in this Section&#160;10.08.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.09&#160;&#160;<I><U>Headings</U>.</I>&#160;&#160;The
    descriptive headings contained in this Agreement are included
    for convenience of reference only and shall not affect in any
    way the meaning or interpretation of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.10&#160;&#160;<I><U>Counterparts</U>.</I>&#160;&#160;This
    Agreement may be executed and delivered (including by facsimile
    or email transmission) in one or more counterparts, and by the
    different parties hereto in separate counterparts, each of which
    when executed shall be deemed to be an original but all of which
    taken together shall constitute one and the same Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-variant: SMALL-CAPS">Section&#160;</FONT>10.11&#160;&#160;<I><U>Joint
    Participation in Drafting This Agreement</U>.</I>&#160;&#160;The
    parties acknowledge and confirm that each of them and their
    respective Representatives have participated jointly in the
    drafting, review, negotiation and revision of this Agreement,
    that it has not been drafted solely by counsel for one party and
    that each party has had the benefit of its independent legal
    counsel&#146;s advice with respect to the terms and provisions
    hereof and its rights and obligations hereunder.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">[Remainder
    of Page&#160;Intentionally Left Blank]
    </FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    IN WITNESS WHEREOF, WebMD and HLTH have caused this Agreement to
    be executed as of the date first written above by their
    respective officers thereunto duly authorized.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WEBMD HEALTH CORP.
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Anthony
    Vuolo</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Anthony Vuolo
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Chief Operating Officer
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HLTH CORPORATION
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Charles
    A. Mele</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Charles A. Mele
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="53%"></TD>
    <TD width="8%"></TD>
    <TD width="39%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Executive Vice President and
</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 61%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    General Counsel
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Exhibit&#160;2.04
    to Merger Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RESTATED<BR>
    CERTIFICATE OF INCORPORATION<BR>
    OF WEBMD HEALTH CORP.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;I
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The name of the corporation (which is hereinafter referred to as
    the &#147;Corporation&#148;) is: WebMD Health Corp.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;II
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address of the Corporation&#146;s registered office in the
    State of Delaware is Corporation Trust&#160;Center, 1209 Orange
    Street, in the City of Wilmington, County of New Castle, 19801.
    The name of its registered agent at such address is The
    Corporation Trust&#160;Company.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;III
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purpose of the Corporation shall be to engage in any lawful
    act or activity for which corporations may be organized and
    incorporated under the General Corporation Law of the State of
    Delaware (the &#147;GCL&#148;).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IV
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.&#160;The total number of shares of stock which the
    Corporation shall have authority to issue is 700,000,000,
    divided into two classes: 50,000,000&#160;shares of Preferred
    Stock, par value $.01 per share (hereinafter referred to as
    &#147;Preferred Stock&#148;); and 650,000,000&#160;shares of
    Common Stock par value $.01 per share (hereinafter referred to
    as &#147;Common Stock&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    B.&#160;The Preferred Stock may be issued from time to time in
    one or more series. The Board of Directors is hereby authorized
    to provide for the issuance of shares of Preferred Stock in one
    or more series and, by filing a certificate pursuant to the
    applicable law of the State of Delaware (hereinafter referred to
    as &#147;Preferred Stock Designation&#148;), to establish from
    time to time the number of shares to be included in each such
    series, and to fix the designation, powers, preferences and
    rights of the shares of each such series and the qualifications,
    limitations and restrictions thereof. The authority of the Board
    of Directors with respect to each series shall include, but not
    be limited to, determination of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;The designation of the series, which may be by
    distinguishing number, letter or title;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;The number of shares of the series, which number the
    Board of Directors may thereafter (except where otherwise
    provided in the Preferred Stock Designation) increase or
    decrease (but not below the number of shares thereof then
    outstanding);
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The amounts payable on, and the preferences, if any,
    of shares of the series in respect of dividends, and whether
    such dividends, if any, shall be cumulative or noncumulative;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Dates at which dividends, if any, shall be payable;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;The redemption rights and price or prices, if any, for
    shares of the series;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vi)&#160;The terms and amount of any sinking fund provided for
    the purchase or redemption of shares of the series;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vii)&#160;Whether the shares of the series shall be convertible
    into or exchangeable for shares of any other class or series, or
    any other security, of the Corporation or any other corporation,
    and, if so, the specification of such other class or series of
    such other security, the conversion or exchange price or prices
    or rate or rates, any adjustments thereof, the date or dates at
    which such shares shall be convertible
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    or exchangeable and all other terms and conditions upon which
    such conversion or exchange may be made;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (viii)&#160;Whether the shares of the series shall be
    convertible into or exchangeable for shares of any other class
    or series, or any other security, of the Corporation or any
    other corporation, and, if so, the specification of such other
    class or series of such other security, the conversion or
    exchange price or prices or rate or rates, any adjustments
    thereof, the date or dates at which such shares shall be
    convertible or exchangeable and all other terms and conditions
    upon which such conversion or exchange may be made;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ix)&#160;Restrictions on the issuance of shares of the same
    series or of any other class or series;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (x)&#160;The voting rights, if any, of the holders of shares of
    the series.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    C.&#160;The Common Stock shall be subject to the express terms
    of the Preferred Stock and any series thereof. Except as may
    otherwise be provided in this Restated Certificate of
    Incorporation or in a Preferred Stock Designation, the holders
    of shares of Common Stock shall be entitled to one vote for each
    such share upon all questions presented to the stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as may otherwise be provided in this Restated Certificate
    of Incorporation or in a Preferred Stock Designation, the Common
    Stock shall have the exclusive right to vote for the election of
    directors and for all other purposes, and holders of Preferred
    Stock shall not be entitled to receive notice of any meeting of
    stockholders at which they are not entitled to vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    D.&#160;The Corporation shall be entitled to treat the person in
    whose name any share of its stock is registered as the owner
    thereof for all purposes and shall not be bound to recognize any
    equitable or other claim to, or interest in, such share on the
    part of any other person, whether or not the Corporation shall
    have notice thereof, except as expressly provided by applicable
    law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    E.&#160;Upon the effectiveness of this Restated Certificate of
    Incorporation pursuant to the GCL, (i)&#160;each share of the
    Corporation&#146;s Class&#160;A Common Stock, par value $.01 per
    share (the &#147;Old Class&#160;A Common Stock&#148;), issued
    and outstanding or held in treasury immediately prior to the
    effectiveness of this Restated Certificate of Incorporation,
    will automatically be reclassified as and converted into
    1&#160;share of Common Stock. Any stock certificate that,
    immediately prior to the effectiveness of this Restated
    Certificate of Incorporation, represented shares of the Old
    Class&#160;A Common Stock will, from and after the effectiveness
    of this Restated Certificate of Incorporation, automatically and
    without the necessity of presenting the same for exchange,
    represent that number of shares of Common Stock into which the
    shares of Old Class&#160;A Common Stock represented by such
    certificate shall have been reclassified pursuant hereto, and
    (ii)&#160;each share of the Corporation&#146;s Class&#160;B
    Common Stock, par value $.01 per share, issued and outstanding
    or held in treasury prior to the effectiveness of this Restated
    Certificate of Incorporation shall be cancelled pursuant to and
    in accordance with the Agreement and Plan of Merger, dated
    June&#160;17, 2009, between the Corporation and HLTH
    Corporation, a Delaware corporation, and no consideration shall
    be issued in respect thereof.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;V
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.&#160;In the event of any voluntary or involuntary
    liquidation, dissolution or winding up of the Corporation,
    subject to any rights, powers and preferences of any outstanding
    Preferred Stock, the holders of shares of Common Stock shall be
    entitled to receive all of the remaining assets of the
    Corporation available for distribution to its stockholders,
    ratably in proportion to the number of shares held by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    B.&#160;Subject to applicable law, and any rights, powers and
    preferences of any outstanding Preferred Stock, the holders of
    the Common Stock shall be entitled to receive dividends, when,
    as and if declared by the Board of Directors out of funds
    lawfully available therefor.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VI
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In furtherance of, and not in limitation of, the powers
    conferred by law, the Board of Directors is expressly authorized
    and empowered:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;to adopt, amend or repeal the Bylaws of the
    Corporation; provided, however, that, notwithstanding any other
    provision of this Restated Certificate of Incorporation or any
    provision of law which might otherwise permit a lesser vote or
    no vote, but in addition to any affirmative vote of the holders
    of any particular class or series of the stock required by law
    or this Restated Certificate of Incorporation, the affirmative
    vote of the holders of at least 80&#160;percent of the voting
    power of the then outstanding Voting Stock, voting together as a
    single class, shall be required in order for the stockholders of
    the Corporation to alter, amend or repeal any provision of the
    Bylaws or to adopt additional bylaws;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;from time to time to determine whether and to what
    extent, and at what times and places, and under what conditions
    and regulations, the accounts and books of the Corporation, or
    any of them, shall be open to inspection of stockholders; and,
    except as so determined or as expressly provided in this
    Restated Certificate of Incorporation or in any Preferred Stock
    Designation, no stockholder shall have any right to inspect any
    account, book or document of the Corporation other than such
    rights as may be conferred by applicable law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Corporation may in its Bylaws confer powers upon the Board
    of Directors in addition to the foregoing and in addition to the
    powers and authorities expressly conferred upon the Board of
    Directors by applicable law. Notwithstanding anything contained
    in this Restated Certificate of Incorporation to the contrary,
    the affirmative vote of the holders of at least 80&#160;percent
    of the voting power of the then outstanding Voting Stock, voting
    together as a single class, shall be required to amend, repeal
    or adopt any provision inconsistent with paragraph (a)&#160;of
    this Article&#160;VI or this sentence. For purposes of this
    Restated Certificate of Incorporation, &#147;Voting Stock&#148;
    shall mean the outstanding shares of capital stock of the
    Corporation entitled to vote generally in the election of
    directors.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VII
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.&#160;Any action required or permitted to be taken by the
    stockholders of the Corporation must be effected at a duly
    called annual or special meeting of stockholders of the
    Corporation and may not be effected by any consent in writing in
    lieu of a meeting of such stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    B.&#160;Special meetings of stockholders of the Corporation for
    any purpose or purposes may be called by the Board of Directors,
    and any power of stockholders to call a special meeting is
    specifically denied.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    C.&#160;Advance notice of stockholder nominations for the
    election of directors and of the proposal by stockholders of any
    other action to be taken by the stockholders at a meeting shall
    be given in such manner as shall be provided in the Bylaws of
    the Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    D.&#160;Notwithstanding anything contained in this Restated
    Certificate of Incorporation to the contrary, the affirmative
    vote of the holders of at least 80&#160;percent of the voting
    power of the then outstanding Voting Stock, voting together as a
    single class, shall be required to amend, repeal or adopt any
    provision inconsistent with this Article&#160;VII.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;VIII
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.&#160;Subject to the rights of the holders of any series of
    Preferred Stock to elect additional directors under specified
    circumstances, the number of directors of the Corporation shall
    be fixed from time to time by the Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    B.&#160;Unless and except to the extent that the Bylaws of the
    Corporation shall so require, the election of directors of the
    Corporation need not be by written ballot.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    C.&#160;The Board of Directors (other than those directors
    elected by the holders of any series of Preferred Stock provided
    for or fixed pursuant to the provisions of Article&#160;IV
    hereof (the &#147;Preferred Stock Directors&#148;)) shall be
    divided into three classes, Class&#160;I, Class&#160;II and
    Class&#160;III. Each class shall consist, as nearly as may be
    possible, of one-third of the number of directors constituting
    the entire Board of Directors. At each annual meeting of the
    stockholders, successors to the class of directors whose term
    expires at that annual meeting shall be elected for a term
    expiring at the third succeeding annual meeting of stockholders.
    If the number of directors (other than Preferred Stock
    Directors) is changed, any increase or decrease shall be
    apportioned among the classes so as to maintain the number of
    directors in each class as nearly equal as possible, and any
    additional director of any class elected to fill a newly created
    directorship resulting from an increase in such class shall hold
    office for a term that shall coincide with the remaining term of
    that class, but in no case shall a decrease in the number of
    directors shorten the term of any incumbent director. A director
    shall hold office until the annual meeting for the year in which
    his term expires and until his successor shall be elected and
    shall qualify, subject, however, to prior death, resignation,
    retirement, disqualification or removal from office.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    D.&#160;Subject to the rights of the holders of any series of
    Preferred stock to elect additional directors under specified
    circumstances, any director may be removed from office only for
    cause, and only by the affirmative vote of the holders of at
    least 80&#160;percent of the voting power of the then
    outstanding Voting Stock, voting together as a single class.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    E.&#160;Subject to the rights of the holders of any series of
    Preferred Stock to elect additional directors under specified
    circumstances, vacancies resulting from death, resignation,
    retirement, disqualification, removal from office or other
    cause, and newly created directorships resulting from any
    increase in the authorized number of directors, may be filled
    only by the affirmative vote of a majority of the remaining
    directors, though less than a quorum of the Board of Directors,
    and directors so chosen shall hold office for a term expiring at
    the annual meeting of stockholders at which the term of office
    of the class to which they have been elected expires and until
    such director&#146;s successor shall have been duly elected and
    qualified. No decrease in the number of authorized directors
    constituting the whole Board of Directors shall shorten the term
    of any incumbent director.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F.&#160;During any period when the holders of any series of
    Preferred Stock have the right to elect additional directors as
    provided for or fixed pursuant to the provisions of
    Article&#160;IV hereof, then upon commencement and for the
    duration of the period during which such right continues:
    (i)&#160;the then otherwise total authorized number of directors
    of the Corporation shall automatically be increased by such
    specified number of directors, and the holders of such Preferred
    Stock shall be entitled to elect the additional directors so
    provided for or fixed pursuant to said provisions, and
    (ii)&#160;each such additional director shall serve until such
    director&#146;s successor shall have been duly elected and
    qualified, or until such director&#146;s right to hold such
    office terminates pursuant to said provisions, whichever occurs
    earlier, subject to his earlier death, disqualification,
    resignation or removal. Except as otherwise provided by the
    Board of Directors in the resolution or resolutions establishing
    such series, whenever the holders of any series of Preferred
    Stock having such right to elect additional directors are
    divested of such right pursuant to the provisions of such stock,
    the terms of office of all such additional directors elected by
    the holders of such stock, or elected to fill any vacancies
    resulting from the death, resignation, disqualification or
    removal of such additional directors, shall forthwith terminate
    and the total authorized number of directors of the Corporation
    shall be reduced accordingly.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    G.&#160;Notwithstanding anything contained in this Restated
    Certificate of Incorporation to the contrary, the affirmative
    vote of the holders of at least 80&#160;percent of the voting
    power of the then outstanding Voting Stock, voting together as a
    single class, shall be required to amend, repeal or adopt any
    provision inconsistent with this Article&#160;VII.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;IX
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A director of the corporation shall not be liable to the
    Corporation or its stockholders for monetary damages for breach
    of fiduciary duty as a director, except to the extent such
    exemption from liability or limitation thereof is not permitted
    under the GCL as the same exists or may hereafter be amended.
    Any amendment, modification or repeal of the foregoing sentence
    shall not adversely affect any right or protection
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of a director of the corporation hereunder in respect of any act
    or omission occurring prior to the time of such amendment,
    modification or repeal.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;X
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.&#160;The Corporation elects to be governed by
    Section&#160;203 of the GCL.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    B.&#160;Notwithstanding anything contained in this Restated
    Certificate of Incorporation to the contrary, the affirmative
    vote of the holders of at least 80&#160;percent of the voting
    power of the then outstanding Voting Stock, voting together as a
    single class, shall be required to amend, repeal or adopt any
    provision inconsistent with this Article&#160;X.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">ARTICLE&#160;XI
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as may be expressly provided in this Restated Certificate
    of Incorporation, the Corporation reserves the right at any time
    and from time to time to amend, alter, change or repeal any
    provision contained in this Restated Certificate of
    Incorporation or a Preferred Stock Designation, and any other
    provisions authorized by the laws of the State of Delaware at
    the time in force may be added or inserted, in the manner now or
    hereafter prescribed herein or by applicable law, and all
    rights, preferences and privileges of whatsoever nature
    conferred upon stockholders, directors or any other persons
    whomsoever by and pursuant to this Restated Certificate of
    Incorporation in its present form or as hereafter amended are
    granted subject to the right reserved in this Article&#160;XI.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Exhibit&#160;2.05
    to Merger Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">HLTH
    Director Classes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HLTH designees to WebMD Board of Directors for the Director
    Class with term expiring in 2010:&#160;Paul&#160;Brooke and
    Kevin Cameron
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HLTH designee to WebMD Board of Directors for the Director Class
    with term expiring in 2011:&#160;Herman&#160;Sarkowsky
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HLTH designee to WebMD Board of Directors for the Director Class
    with term expiring in 2012:&#160;Joseph&#160;E.&#160;Smith
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
